WO2008148013A1 - Films de polymères pour le revêtement des dispositifs médicaux - Google Patents

Films de polymères pour le revêtement des dispositifs médicaux Download PDF

Info

Publication number
WO2008148013A1
WO2008148013A1 PCT/US2008/064732 US2008064732W WO2008148013A1 WO 2008148013 A1 WO2008148013 A1 WO 2008148013A1 US 2008064732 W US2008064732 W US 2008064732W WO 2008148013 A1 WO2008148013 A1 WO 2008148013A1
Authority
WO
WIPO (PCT)
Prior art keywords
polymer
substrate
layer
coating
depositing
Prior art date
Application number
PCT/US2008/064732
Other languages
English (en)
Inventor
Douglas Taylor
James Mcclain
Original Assignee
Micell Technologies, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Micell Technologies, Inc. filed Critical Micell Technologies, Inc.
Priority to EP08756215.3A priority Critical patent/EP2170418B1/fr
Priority to JP2010510441A priority patent/JP2010527746A/ja
Priority to CA2688314A priority patent/CA2688314C/fr
Priority to AU2008256684A priority patent/AU2008256684B2/en
Priority to CN200880100102.3A priority patent/CN101815540B/zh
Priority to US12/601,101 priority patent/US8900651B2/en
Publication of WO2008148013A1 publication Critical patent/WO2008148013A1/fr
Priority to IL202321A priority patent/IL202321A/en

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05D—PROCESSES FOR APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05D1/00—Processes for applying liquids or other fluent materials
    • B05D1/02—Processes for applying liquids or other fluent materials performed by spraying
    • B05D1/025—Processes for applying liquids or other fluent materials performed by spraying using gas close to its critical state
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/28—Materials for coating prostheses
    • A61L27/34—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08—Materials for coatings
    • A61L31/10—Macromolecular materials
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05D—PROCESSES FOR APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05D1/00—Processes for applying liquids or other fluent materials
    • B05D1/02—Processes for applying liquids or other fluent materials performed by spraying
    • B05D1/04—Processes for applying liquids or other fluent materials performed by spraying involving the use of an electrostatic field
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2420/00—Materials or methods for coatings medical devices
    • A61L2420/02—Methods for coating medical devices
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05D—PROCESSES FOR APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05D2401/00—Form of the coating product, e.g. solution, water dispersion, powders or the like
    • B05D2401/90—Form of the coating product, e.g. solution, water dispersion, powders or the like at least one component of the composition being in supercritical state or close to supercritical state
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05D—PROCESSES FOR APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05D5/00—Processes for applying liquids or other fluent materials to surfaces to obtain special surface effects, finishes or structures
    • B05D5/08—Processes for applying liquids or other fluent materials to surfaces to obtain special surface effects, finishes or structures to obtain an anti-friction or anti-adhesive surface
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05D—PROCESSES FOR APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05D5/00—Processes for applying liquids or other fluent materials to surfaces to obtain special surface effects, finishes or structures
    • B05D5/08—Processes for applying liquids or other fluent materials to surfaces to obtain special surface effects, finishes or structures to obtain an anti-friction or anti-adhesive surface
    • B05D5/083—Processes for applying liquids or other fluent materials to surfaces to obtain special surface effects, finishes or structures to obtain an anti-friction or anti-adhesive surface involving the use of fluoropolymers

Definitions

  • Medical devices often must be shielded from interacting with body fluids in vivo.
  • devices that are electrical in nature for example, such as pacemakers and other "active" implants for sensing, delivery of therapeutics and/or active control of various bodily functions should be protected.
  • One prevalent method used to provide this protection is to weld the device inside a titanium or other biocompatible metal "can.”
  • Another method to provide the shield necessary to protect a medical device from interaction with bodily fluids in vivo is polymer coating the device. Polymer coating such "active" implants has significant technical challenges and limitations which have made polymer coatings relatively unsuccessful as a means of sealing the devices.
  • Solvent-less coating processes e.g. vapor deposition, plasma deposition, dry powder coating, etc. also have limitations in providing seals to active devices. Solvent-less coating processes all require very aggressive conditions that could damage the device - such as elevated temperatures to cure a dry powder coated device.
  • solvent-based and solvent-less it is often difficult to achieve coatings of uniform thicknesses and prevent the occurrence of defects (e.g. bare spots, webs, pools, clumps). As the size of the substrate decreases, and as the mechanical complexity increases, it grows increasingly difficult to uniformly coat all surfaces of a substrate. Supplemental steps, therefore, are sometimes necessary to assure proper coating, including, for example, multiple coating steps and/or drying between or after the coating steps (in solvent-based systems).
  • a cost-effective, easy to apply polymer-based coatings and coating methods to seal a substrate, where the collection process on the substrate is efficient, the coating produced is conformal, substantially defect-free and uniform, and the composition of the coating can be regulated and controlled is provided herein.
  • the method and coatings provide a seal which is impermeable and/or imperveous to gas and/or fluid.
  • the seal can be applied to a variety of substrates, including, but not limited to, implantable medical devices that are electrical in nature such as pacemakers and other "active" implants, which can shield the substrates from interacting with body fluids in vivo.
  • the present invention relates to coatings and methods for depositing a coating comprising a polymer and a impermeable dispersed solid onto a substrate.
  • a coating comprising a polymer and a impermeable dispersed solid onto a substrate.
  • novel, easy to apply, polymer-based coatings and coating methods to seal and, thereby, shield, for example, medical devices that are electrical in nature such as pacemakers and other "active" implants from interacting with body fluids in vivo in a manner that disrupts the substrate's (e.g. active medical device's) intended functions and/or proper functioning, if any, or in a manner that has unintended consequences within and/or to the patient.
  • novel, easy to apply, polymer-based coatings and coating methods to seal for example, implantable medical devices that are electrical in nature such as pacemakers and other "active" implants and, thereby, shield the body from degradation products, leachants, and extractables from the medical device.
  • the coatings and methods provided herein result in a collection process on the substrate that is efficient, a conformal, substantially defect-free, and uniform coating, and a regulatable and controllable coating composition.
  • the coating structures and methods provided herein not only avoid the problems of polymer coatings (solvent-based, and solvent-less), but they also improve the barrier properties of polymer films for use as a seal upon, for example, biologically implanted devices.
  • e-RESS e-RESS
  • e- SEDS e- SEDS
  • eDPC e-DPC
  • a coating comprising electrostatically captured polymer particles (generated by eRESS, eSEDS or eDPC) with either concurrent or sequential captured impermeable particles (by eDPC, eRESS, eSEDS) on a medical implant substrate.
  • a method is also provided for electrostatically capturing polymer particles (generated by eRESS, eSEDS or eDPC) with either concurrent or sequential capturing impermeable particles (by eDPC, eRESS, eSEDS) on a medical implant substrate.
  • the method comprises sintering the medical implant substrate with a compressed gas at conditions adequate to cause flow of the polymer particles into a continuous film on the substrate.
  • the polymers that could be used in the coatings or methods provided herein are all solution or thermally processible polymers (e.g. acrylates, olefins, fluoropolymers, urethanes, etc.).
  • a polymer (or polymers) could be used with known biocompatibility and high resistance to chemical degradation such as polymers of fluorinated olefins.
  • the impermeable particles that could be used in this coating method includes all inorganic particles that can be obtained in the micron and/or sub-micron size range (for example, various compositions of clay, metal-oxides, ceramics, etc.) [0013]
  • a polymer coating is sufficient to provide the requisite sealing properties.
  • the coating would contain a polymer continuous phase with particles embedded therein. The existence and distribution of the particles cases an increase in the barrier properties of the film to small molecules and gases by blocking diffusion pathways.
  • the surface of the particles is chemically modified to provide greater dispersion and incorporation into the polymer film.
  • the method comprises chemically modifying the surface of the particles to provide greater dispersion and incorporation into the polymer film.
  • a highly polar particle e.g. clay, SiO2, TiO2, etc.
  • a highly non- polar polymer e.g. polymeric fluorinated olefins
  • the process comprises binding or bonding a non-polar chemistry to the surface of the particle prior to incorporation into the powder-coating and sintering process.
  • stacked polymer films with an intervening impermeable layer which could provide similar protection for sensitive devices in vivo without the difficulty associated with welding metal cans around the device.
  • polymers to be used in the processes and in the coatings provided herein are inherently hydrophobic, thereby greatly reducing the likelihood of penetration of biological fluids.
  • fluoropolymers as a class yield high surface energy surfaces that meet this requirement.
  • surfaces created from such polymers in some cases act as membranes through which water vapor transport can occur.
  • a second layer that can trap any water vapor that might permeate the fluoropolymer membrane is provided.
  • the method comprises depositing a hydrophilic polymer layer such as a silicon based polymer over the initial fluoropolymer layer.
  • Silicon based polymers can be designed to possess differing degrees of hydrophilicity and therefore trap any water vapor that might permeate the fluoropolymer layer membrane.
  • the silicon-based polymer is reduced to native silicon and metallized with titanium.
  • a third layer of fluoropolymer is deposited to encapsulate the silicon based polymer layer between the fluropolymer layers.
  • the coating comprises multiple alternating layers of fluoropolymers and silicon based polymers.
  • the method comprises alternating multiple layers of the silicon based polymer and the fluropolymer.
  • the coating is designed to remain impermeable and/or impervious to gas and/or fluid for at least as long as the expected life span (e.g., period of time inside a subjects body) of the device and/or substrate it coats.
  • One aspect of the invention provides methods for depositing a coating comprising a polymer and impermeable dispersed solid on a substrate, comprising discharging at least one impermeable dispersed solid in dry powder form through a first orifice; discharging at least one polymer in dry powder form through a second orifice; depositing the polymer and/or impermeable dispersed solids onto said substrate, wherein an electrical potential is maintained between the substrate and the impermeable dispersed solid and/or polymer particles, thereby forming said coating; and sintering said coating under conditions that do not substantially affect the substrate.
  • the impermeable dispersed solid is dispersed uniformly on all exposed surfaces of the substrate.
  • the impermeable dispersed solid is impermeable and/or impervious to gas. In some embodiments, the impermeable dispersed solid is impermeable and/or impervious to fluid. In some embodiments, the impermeable dispersed solid is impermeable and/or impervious to biological material. [0018] In some embodiments, the impermeable dispersed solid comprises nanoparticles, such as, for example, a polyurethane adhesive nanocomposite (organically modified montmorillonite and polyurethane). In some embodiments, the oxygen transmission rate across the coating is at most about 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, or 70%.
  • the water vapor permeation through the coating is at most about 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, or 70%.
  • “about” refers to variations of .01% to .1%, or 1% to 5%.
  • the size, resistivity and moisture content of the polymer and impermeable dispersed solid may vary widely based on the conditions used, desired particle sizes are typically in the range of 0.01 ⁇ m - 2500 ⁇ m, and more preferably in the range of 0.01 ⁇ m - 100 ⁇ m, resistivity is typically in the range of from about 1 O ⁇ m to about 1024 ⁇ m and moisture content is less than 5% by weight.
  • the molecular weight range of the polymer is from about 5,000 a.u. to about 100,000 a.u.
  • the first and second orifices are provided as one single orifice wherein the impermeable dispersed solid and polymer may be mixed together prior to discharging.
  • the impermeable dispersed solid and polymer particles may be discharged simultaneously or in succession.
  • the method further comprises discharging a third dry powder comprising a second impermeable dispersed solid whereby a coating comprising at least two different impermeable dispersed solids is deposited on said substrate.
  • the impermeable dispersed solid is prepared by milling, jet-milling, granulation, spray drying, crystallizing or fluidizing.
  • the impermeable dispersed solid and/or the polymer becomes electrostatically charged prior to deposition, and the substrate may be electrically grounded. In a preferred embodiment, the substrate is electrostatically charged.
  • the polymer and impermeable dispersed solid are discharged using a gas based propellant, which typically comprises carbon dioxide, nitrous oxide, hydrofluorocarbons, chlorofluorocarbons, helium, nitrogen, compressed air, argon, or volatile hydrocarbons with a vapor pressure greater than 750 Torr at 20oC, and is preferably carbon dioxide.
  • a gas based propellant typically comprises carbon dioxide, nitrous oxide, hydrofluorocarbons, chlorofluorocarbons, helium, nitrogen, compressed air, argon, or volatile hydrocarbons with a vapor pressure greater than 750 Torr at 20oC, and is preferably carbon dioxide.
  • the impermeable dispersed solid comprises at least one drug.
  • the ratio of impermeable dispersed solid to polymer is from about 1 : 1000 to about 3:10.
  • the amount of impermeable dispersed solid will depend on the particular dispersed solid being employed, the type of substrate, and the medical condition being treated, [0023]
  • Yet another aspect of the invention provides methods for depositing a coating comprising a polymer and a impermeable dispersed solid on a substrate, comprising discharging at least one impermeable dispersed solid in a therapeutically desirable morphology in dry powder form through a first orifice; forming a supercritical or near supercritical fluid mixture that includes at least one supercritical fluid solvent and at least one polymer and discharging said supercritical or near supercritical fluid solution through a second orifice under conditions sufficient to form solid particles of the polymer; depositing the polymer and/or impermeable dispersed solids onto said substrate, wherein an electrical potential is maintained between the substrate and the impermeable dispersed solids and/or polymer particles, thereby forming said coating and sintering said coating under conditions that do not substantially disrupt the substrate's (e.g.
  • each of the above methods may be carried out from about O 0 C to about 80 0 C and from about 0, 1 atmospheres to about 73 atmospheres, in either open or closed vessel.
  • the substrate is a biomedical implant which may be a.
  • a stent e.g., vascular stents
  • electrode e.g., vascular stents
  • implantable cardioverter a housing for an implantable pacemaker, a housing for an implantable defibrillator, a housing for an implantable cardioverter, sensor, drug delivery device, therapy delivery device, device comprising telemetry capability, device comprising electrical impulses, diagnostic device, measurement device, joint, screw, rod, ophthalmic implant, femoral pin, bone plate, graft, anastomotic device, perivascular wrap, suture, staple, shuntsfor hydrocephalus, dialysis graft, colostomy bag attachment device, ear drainage tube, lead for pace makers and implantable cardioverters and defibrillators, vertebral disk, bone pin, suture anchor, hemostatic barrier, clamp, screws, plate, clip, vascular implant, tissue adhesive, sealant, tissue scaffolds, shunts, opthalmic implant, prosthetic, shunt, ur
  • the thickness of said coating is from about 1 to about lOO ⁇ m, preferably about lO ⁇ m, and the variation in the thickness along said coating is within 0.5 ⁇ m, within 0.25 ⁇ m, within 0.1 ⁇ m or within 10% of the total thickness of said coating, within 5% of the total thickness of said coating, or within 2.5% of the total thickness of said coating.
  • the impermeable dispersed solid is positioned at a selected distance from top of said coating. In further embodiments, the impermeable dispersed solid is positioned at about midway between the top of said coating and the substrate surface.
  • the variability in the amount of impermeable dispersed solid deposited on said substrate is 20% or less, 15% or less, 10% or less, 5% or less, for a batch of substrates coated at the same tune. Preferably the variability is 5% or less.
  • the methods further comprise depositing a top layer on said coating wherein said top layer is a polymer film.
  • the polymer film has a thickness of 0.5 to 10 microns, and can be deposited by an eRESS or eSEDS, or a eDPC process.
  • the polymer film is formed by depositing a single polymer and for example by depositing substantially pure PBMA.
  • the invention further relates to the use of a supercritical solution comprising a second fluid in it- supercritical state.
  • the addition of a second fluid in its supercritical state is to act as a flammability suppressor.
  • a second fluid is used, wherein said second fluid has critical parameters lower than the first fluid's critical parameters, and therefore lowers the critical properties of the mixture/solution enabling access to the mixture supercritical state.
  • the supercritical solution comprises isobutylene.
  • the supercritical fluid comprises isobutylene and carbon dioxide as a second fluid.
  • Other embodiments of the invention provide a way to dissolve two polymers in a supercritical solvent.
  • said two polymers are PEVA and PBMA.
  • a supercritical solution comprising two polymers is used to create a RESS spray of the polymers generating ⁇ 10 to 100 nm particles of each polymer.
  • PEVA and PBMA are dissolved in a supercritical solvent that further comprises CO2 to act as a fire suppressor in the event of an ignition source causing a fire.
  • Figure 1 Schematic Representation of the Coating and Sintering Process Apparatus.
  • the present invention relates to coatings and methods for depositing a coating comprising a polymer and a impermeable dispersed solid onto a substrate.
  • a coating comprising a polymer and a impermeable dispersed solid onto a substrate.
  • novel, easy to apply, polymer-based coatings and coating methods to seal and, thereby, shield, for example, implantable medical devices that are electrical in nature such as pacemakers and other "active" implants from interacting with body fluids in vivo in a manner that disrupts the medical device's intended functions and proper functioning, or in a manner that has unintended consequences within and/or to the patient.
  • novel, easy to apply, polymer-based coatings and coating methods to seal for example, implantable medical devices that are electrical in nature such as pacemakers and other "active" implants and, thereby, shield the body from degradation products, leachants, extractables from the medical device.
  • the coatings and methods provided herein result in a collection process on the substrate that is an efficient, conformal, substantially defect-free, and uniform coating, and a regulatable and controllable coating composition.
  • the coating structures and methods provided herein not only avoid the problems of polymer coatings (solvent-based, and solvent-less), but they also improve the barrier properties of polymer films for use as a seal upon, for example, biologically implanted devices.
  • a composite material coating containing polymer to provide increased barrier properties for gases such as water vapor, aid method of creating such coating.
  • a composite material coating containing polymer plus a impermeable dispersed solid to provide increased barrier properties for gases such as water vapor, and method of creating such coating.
  • the a method for electrostatic capture of polymer particles upon a substrate followed by sintering of these particles by exposure to compressed gasses are free from elevated temperatures, solvent exposure, plasma environments, and other challenges associated with traditional polymer coating methods.
  • a coating comprising electrostatically captured polymer particles (generated by eRESS, eSEDS or eDPC) alone or optionally with either concurrent or sequential captured impermeable particles (by eDPC, eRESS, eSEDS) on a medical implant substrate.
  • a method is also provided for electrostatically capturing polymer particles (generated by eRESS, eSEDS or eDPC) alone or with either concurrent or sequential capturing impermeable particles (by eDPC, eRESS, eSEDS) on a medical implant substrate.
  • the method comprises sintering the medical implant substrate with a compressed gas at conditions adequate to cause flow of the polymer particles into a continuous film on the substrate.
  • the polymers that could be used in the coatings or methods provided herein are all solution or thermally processible polymers (e.g. acrylates, olefins, fluoropolymers, urethanes, etc.).
  • a polymer (or polymers) could be used with known biocompatibility and high resistance to chemical degradation such as polymers of fluorinated olefins.
  • the impermeable particles that could be used in this coating method includes all inorganic particles that can be obtained in the micron and/or sub-micron size range. For example various compositions of clay, metal-oxides, ceramics, etc. [0043]
  • the resulting film would contain a polymer continuous phase optionally with particles embedded therein. The existence and distribution of the particles causes an increase in the barrier properties of the film to small molecules and gases by blocking diffusion pathways.
  • the surface of the particles is chemically modified to provide greater dispersion and incorporation into the polymer film.
  • the method comprises chemically modifying the surface of the particles to provide greater dispersion and incorporation into the polymer film.
  • a highly polar particle e.g. clay, SiO2, TiO2, etc.
  • a highly non-polar polymer e.g. polymeric fluorinated olefins
  • the process comprises binding or bonding a non-polar chemistry to the surface of the particle prior to incorporation into the powder-coating and sintering process.
  • polymers to be used in the processes and in the coatings provided herein are inherently hydrophobic, thereby greatly reducing the likelihood of penetration of biological fluids.
  • fluoropolymers as a class yield high surface energy surfaces mat meet this requirement.
  • surfaces created from such polymers in some cases act as membranes through which water vapor transport can occur.
  • a second layer that can trap any water vapor that might permeate the fluoropolymer membrane is provided.
  • the method comprises depositing a hydrophilic polymer layer such as a silicon based polymer over the initial fluoropolymer layer.
  • a hydrophilic polymer layer such as a silicon based polymer
  • Silicon based polymers can be designed to possess differing degrees of hydrophilicity and therefore trap any water vapor that might permeate the fluoropolymer layer membrane.
  • the silicon-based polymer is reduced to native silicon and metallized with titanium.
  • a highly absorbent material is used as the water-vapor trapping material.
  • the highly absorbent material comprises a hydrophilic polymer.
  • highly absorbent material comprises a superabsorbent polymer.
  • a third layer of fluoropolymer is deposited to encapsulate the silicon based polymer layer between the fluropolymer layers.
  • the coating comprises multiple alternating layers of fluoropolymers and silicon based polymers.
  • the method comprises alternating multiple layers of the silicon based polymer and the fluropolymer.
  • the coating is designed to remain impermeable for at least as long as the expected life span of the device and/or substrate it coats.
  • One aspect of the invention provides methods for depositing a coating comprising a polymer and impermeable dispersed solid on a substrate, comprising discharging at least one impermeable dispersed solid in dry powder form through a first orifice; discharging at least one polymer in dry powder form through a second orifice; depositing the polymer and/or impermeable dispersed solids onto said substrate, wherein an electrical potential is maintained between the substrate and the impermeable dispersed solid and/or polymer particles, thereby forming said coating; and sintering said coating under conditions that do not substantially affect the substrate.
  • the impermeable dispersed solid is dispersed uniformly on all exposed surfaces of the substrate.
  • the impermeable dispersed solid comprises a nanoparticle, such as, for example, a polyurethane adhesive nanocomposite (organically modified montmorillonite and polyurethane).
  • the oxygen transmission rate across the coating is at most about 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, or 70%.
  • the water vapor permeation through the coating is at most about 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, or 70%.
  • “about” refers to variations of .01% to .1%, or 1% to 5%.
  • the impermeable dispersed solid comprises a nanoparticle that is impervious to small particle transport.
  • the nanoparticle comprises at least one of a ceramic and a metal.
  • the nanoparticle comprises clay.
  • the nanoparticle comprises silica.
  • the nanoparticle comprises titanium oxide.
  • the nanoparticle does not include nickel.
  • the nanoparticle does not include copper.
  • the small particle transmission rate across the coating is at most about 0.001%, 0.01%, 0.1%, 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, or 70%.
  • the oxygen transmission rate across the coating is at most about 0.001%, 0.01%, 0.1%, 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, or 70%.
  • the water vapor permeation through the coating is at most about 0.001%, 0.01%, 0.1%, 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, or 70%.
  • “about” refers to variations of .001% to .01%, 0.01% to 0.1%, or 1% to 5%.
  • the size, resistivity and moisture content of the polymer and impermeable dispersed solid may vary widely based on the conditions used, desired particle sizes are typically in the range of 0.01 ⁇ m - 2500 ⁇ m, and more preferably in the range of 0.01 ⁇ m - 100 ⁇ m, resistivity is typically in the range of from about 106 ⁇ m to about 1024 ⁇ m and moisture content is less than 5% by weight.
  • the molecular weight range of the polymer is from about 5,000 a.u. to about 100,000 a.u.
  • the first and second orifices are provided as one single orifice wherein the impermeable dispersed solid and polymer may be mixed together prior to discharging.
  • the impermeable dispersed solid and polymer particles may be discharged simultaneously or in succession.
  • the method further comprises discharging a third dry powder comprising a second impermeable dispersed solid whereby a coating comprising at least two different impermeable dispersed solids is deposited on said substrate.
  • the impermeable dispersed solid is prepared by milling, jet-milling, granulation, spray drying, crystallizing or fluidizing.
  • the impermeable dispersed solid and/or the polymer becomes electrostatically charged prior to deposition, and the substrate may be electrically grounded, hi a preferred embodiment, the substrate is electrostatically charged.
  • the polymer and impermeable dispersed solid are discharged using a gas based propellant, which typically comprises carbon dioxide, nitrous oxide, hydrofluorocarbons, chlorofluorocarbons, helium, nitrogen, compressed air, argon, or volatile hydrocarbons with a vapor pressure greater than 750 Torr at 20oC, and is preferably carbon dioxide.
  • the impermeable dispersed solid comprises at least one drag.
  • the ratio of impermeable dispersed solid to polymer is from about 1 :1000 to about 3: 10. In some embodiments, the amount of impermeable dispersed solid will depend on the particular dispersed solid being employed, the type of substrate, and the medicai condition being treated.
  • Yet another aspect of the invention provides methods for depositing a coating comprising a polymer and a impermeable dispersed solid on a substrate, comprising discharging at least one a impermeable dispersed solid in a therapeutically desirable morphology in dry powder form through a first orifice; forming a supercritical or near supercritical fluid mixture that includes at least one supercritical fluid solvent and at least one polymer and discharging said supercritical or near supercritical fluid solution through a second orifice under conditions sufficient to form solid particles of the polymer; depositing the polymer and/or impermeable dispersed solids onto said substrate, wherein an electrical potential is maintained between the substrate and the impermeable dispersed solids and/or polymer particles, thereby forming said coating and sintering said coating under conditions that do not substantially disrupt the substrate's (e.g. implantable active medical device's) intended functions and proper functioning, if any, or that have unintended consequences within and/or to the patient once implanted.
  • substrate's
  • the substrate is a stent (e.g., vascular stents), electrode, catheter, lead, implantable pacemaker, implantable cardioverter, a housing for an implantable pacemaker, a housing for an implantable defibrillator, a housing for an implantable cardioverter, sensor, drug delivery device, therapy delivery device, device comprising telemetry capability, device comprising electrical impulses, diagnostic device, measurement device, joint, screw, rod, ophthalmic implant, femoral pin, bone plate, graft, anastomotic device, perivascular wrap, suture, staple, shuntsfor hydrocephalus, dialysis graft, colostomy bag attachment device, ear drainage tube, lead for pace makers and implantable cardioverters and defibrillators, vertebral disk, bone
  • the thickness of said coating is from about 1 to about lOO ⁇ m, preferably about lO ⁇ m, and the variation in the thickness along said coating is within 0.5 ⁇ m, within 0.25 ⁇ m, within O.l ⁇ m or within 10% of the total thickness of said coating, within 5% of the total thickness of said coating, or within 2.5% of the total thickness of said coating.
  • the impermeable dispersed solid is positioned at a selected distance from top of said coating. In further embodiments, the impermeable dispersed solid is positioned at about midway between the top of said coating and the substrate surface.
  • the variability in the amount of impermeable dispersed solid deposited on said substrate is 20% or less, 15% or less, 10% or less, 5% or less, for a batch of substrates coated at the same time.
  • the variability is 5% or less
  • the methods further comprise depositing a top layer on said coating wherein said top layer is a polymer film.
  • the polymer film has a thickness of 0.5 to 10 microns, and can be deposited by an eRESS or eSEDS, or a eDPC process.
  • the polymer film is formed by depositing a single polymer and can be formed by depositing substantially pure PBMA.
  • the invention further relates to the use of a supercritical solution comprising a second fluid in its supercritical state.
  • the addition of a second fluid in its supercritical state is to act as a flammability suppressor.
  • a second fluid is used, wherein said second fluid has critical parameters lower than the first fluid's critical parameters, and therefore lowers the critical properties of the mixture/solution enabling access to the mixture supercritical state.
  • the supercritical solution comprises isobutylene.
  • the supercritical fluid comprises isobutylene and carbon dioxide as a second fluid.
  • Othe ⁇ embodiments of the invention provide a way to dissolve two polymers in a supercritical solvent.
  • said two polymers are PEVA and PBMA.
  • a supercritical solution comprising two polymers is used to create a RESS spray of the polymers generating -10 to 100 run particles of each polymer.
  • PEVA and PBMA are dissolved in a supercritical solvent that further comprises CO 2 to act as a fire suppressor in the event of an ignition source causing a fire.
  • One aspect of the invention entails the deposition of the a impermeable dispersed solid as dry powders, using electrostatic capture to attract the powder particles to the substrate.
  • Dry powder spraying is well known in the art, and dry powder spraying coupled with electrostatic capture has been described, for example in US Patents 5,470,603 6,319,541 or 6,372,246.
  • the deposition of the polymer can be performed in any number of standard procedures, as the morphology of the polymer, so long as it provides coatings possessing the desired properties (e.g. thickness, conformity, defect-free, uniformity), and are free from elevated temperatures, solvent exposure, plasma environments, and other challenges associated with traditional polymer coating methods.
  • the second step of the coating process involves taking the substrates that have been coated with impermeable dispersed solids and polymers and subjecting them to a sintering process that takes place under conditions free from elevated temperatures, solvent exposure, plasma environments, and other challenges associated with traditional polymer coating methods.
  • the sintering process as used in the current invention refers to the process by which the co-deposited impermeable dispersed solid -polymer matrix become fused and adherent to the substrate by treatment of the coated substrate with a compressed gas, compressed liquid, or supercritical fluid that is a non-solvent for the polymers and the impermeable dispersed solid(s), but a plasticizing agent for the polymer.
  • the sintering process takes place under conditions (e.g. mild temperatures), and using benign fluids (e.g. supercritical carbon dioxide) which will not affect the active substrate or its subsequent function, if any.
  • One aspect of the invention is the combination of two or more of the e-DPC, e-RESS and e-SEDS spraying techniques.
  • a specific aspect of the invention involves the dry powder spraying of impermeable dispersed solid, in a preferred particle size, into the same capture vessel as a polymer that is also dry powder sprayed, whereby the spraying of the impermeable dispersed solid and the polymer is sequential or simultaneous.
  • the invention involves the e-DPC spraying of the impermeable dispersed solid, into the same capture vessel as a polymer that is sequentially or simultaneously sprayed by the eRESS spray process. In some embodiments, the invention involves the e-DPC spraying of the impermeable dispersed solid, into the same capture vessel as a polymer that is sequentially or simultaneously sprayed by the eSEDS spray process. In some embodiments, the invention involves the e-DPC spraying of the impermeable dispersed solid, into the same capture vessel as a polymer that is sequentially or simultaneously sprayed by the eDPC spray process.
  • the invention involves the e-RESS spraying of the impermeable dispersed solid, into the same capture vessel as a polymer that is sequentially or simultaneously sprayed by the eRESS spray process. In some embodiments, the invention involves the e-RESS spraying of the impermeable dispersed solid, into the same capture vessel as a polymer that is sequentially or simultaneously sprayed by the eSEDS spray process. In some embodiments, the invention involves the e-RESS spraying of the impermeable dispersed solid, into the same capture vessel as a polymer that is sequentially or simultaneously sprayed by the eDPC spray process.
  • the invention involves the e-SEDS spraying of the impermeable dispersed solid, into the same capture vessel as a polymer that is sequentially or simultaneously sprayed by the eRESS spray process. In some embodiments, the invention involves the e-SEDS spraying of the impermeable dispersed solid, into the same capture vessel as a polymer that is sequentially or simultaneously sprayed by the eSEDS spray process. In some embodiments, the invention involves the e-SEDS spraying of the impermeable dispersed solid, into the same capture vessel as a polymer that is sequentially or simultaneously sprayed by the eDPC spray process. [0071] Any combination of the above processes is contemplated by this aspect of the invention.
  • the substrates that have been coated with impermeable dispersed solid and polymers, as described in the above embodiments are then subjected to a sintering process.
  • the sintering process takes place under conditions free from elevated temperatures, solvent exposure, plasma environments, and other challenges associated with traditional polymer coating methods, and refers to a process by which the co-deposited impermeable dispersed solid-polymer matrix, becomes fused and adherent to the substrate. This is achieved by treating the coated substrate with a compressed gas, compressed liquid or supercritical fluid that is a non-solvent for the polymers, the impermeable dispersed solids, but a plasticizing agent for the polymer.
  • the sintering process takes place under conditions (e.g.
  • Substrate refers to any surface upon which it is desirable to deposit a coating comprising a polymer or a mix of polymer with or without impermeable dispersed solid, or hydrophobic polymers and a water-vapor-trapping material, wherein the coating process does not substantially disrupt the substrate's (e.g. implantable active medical device's) intended functions and/or proper functioning, if any, or in a manner that has unintended consequences within and/or to the patient.
  • substrate's e.g. implantable active medical device's
  • Biomedical implants are of particular interest for the present invention; however the present invention is not intended to be restricted to this class of substrates. Those of skill in the art will appreciate alternate substrates that could benefit from the coating process described herein, such as temporary implantable devices, diagnostic tests or kits.
  • Biomedical implant refers to any implant for insertion into the body of a human or animal subject, including but not limited to a stent (e.g., vascular stents), electrode, catheter, lead, implantable pacemaker, implantable cardioverter, a housing for an implantable pacemaker, a housing for an implantable defibrillator, a housing for an implantable cardioverter, sensor, drug delivery device, therapy delivery device, device comprising telemetry capability, device comprising electrical impulses, diagnostic device, measurement device, joint, screw, rod, ophthalmic implant, femoral pin, bone plate, graft, anastomotic device, perivascular wrap, suture, staple, shuntsfor hydrocephalus, dialysis graft, colostomy bag attachment device, ear drainage tube, lead for pace makers and implantable cardioverters and defibrillators, vertebral disk, bone pin, suture anchor, hemostatic barrier, clamp, screws, plate, clip,
  • the implants may be formed from any suitable material, including but not limited to organic polymers (including stable or inert polymers and biodegradable polymers), metals, inorganic materials such as silicon, and composites thereof, including layered structures with a core of one material and one or more coatings of a different material.
  • Subjects into which biomedical implants of the invention may be applied or inserted include both human subjects (including male and female subjects and infant, juvenile, adolescent, adult and geriatric subjects) as well as animal subjects (including but not limited to dog, cat, horse, monkey, etc.) for veterinary purposes.
  • the biomedical implant is an implantable pacemaker, cardioverter or defibrillator, or another active device or any implantable (permanent or temporary) device requiring sealing to prevent gas or fluid permeation.
  • “Active” or “Active medical device” as used herein refers to medical devices that are electrical in nature, such as pacemakers and other medical devices for sensing, delivery of therapeutics and/or active control of various bodily functions.
  • “Medical device” as used herein can refer to biological implants as defined herein active or inactive, A medical device may be permanently implantable, temporarily implantable, entirely implantable (such as, for example, an implantable defibrillator), partially implantable (such as, for example, a sensing drainage catheter) and/or can refer to devices used on or in a patient during a diagnostic or therapeutic procedure, including during an invasive surgery or during a minimally invasive surgery.
  • a medical device includes any instrument, apparatus, appliance, material or other article, whether used alone or in combination, including any software necessary for its proper application intended by the manufacturer to be used for human beings for the purpose of: diagnosis, prevention, monitoring, treatment or alleviation of disease, alleviation of pain, diagnosis, monitoring, treatment, alleviation of or compensation for an injury or handicap, investigation, replacement or modification of the anatomy or of a physiological process, control of conception, and which does not achieve its principal intended action in or on the human body by pharmacological, immunological or metabolic means, but which may be assisted in its function by such means.
  • an insulin pump implanted in a diabetic person which dispenses insulin stored in the pump into the patient's blood based upon glucose levels sensed by the pump is a medical device (and is an active medical device and a biological implant).
  • Biological material as used herein can refer a biological material in gas or fluid state including small solid particles
  • Defect can refer to, but is not limited to: surface topology variability, such as a clump, a web, or a pool; a through-layer deficiency, such as a bare spot, a fracture, a crack, a pin hole, a thin spot, a blemish; or a under-layer defect, such as a bubble between layers, a bubble beneath a layer, matter trapped beneath a layer or between layers of coating which is not a part of the substrate or of the layer(s), such as dust, liquid, gas, or particulate, An under-layer defect might affect the seal of a substrate device.
  • an under-layer water vapor bubble might act as a sink for diffusion of water vapor, making an active device more prone to interacting with the vapor and/or potentially with body fluids in vivo in a manner that disrupts the substrate's (e.g. active device's) intended functions and/or proper functioning, if any, or in a manner that has unintended consequences within and/or to the patient.
  • any other defect through-layer, or surface topology variability
  • any other defect which allows gas or fluids to interact with the substrate can potentially result in disruption of the substrate's (e.g.
  • Conformal coating can refer to a protective covering that conforms to the configuration of the objects coated. A covering that is conformal covers susbtantial ⁇ y all surfaces with a uniform layer.
  • a coating layering process may confomally coat a device with a 10 micron coating (of a layer or of layers) plus or minus 10%, which results in a 10 micron plus or minus 10% coating on every external surface of the device that is at least about 20 microns apart from another external surface of the device (external surfaces of the device that are closer may appear to have thicker coatings as the coatings on of the two nearby surfaces join).
  • “Seal” or “Substantially seal” as used herein can refer to coating that substantially shields a substrate from interacting with materials (fluids, gases, solids), in a manner that disrupts the substrate's intended functions and/or proper functioning, if any, or in a manner that has unintended consequences within and/or to the patient.
  • the term(s) can refer to coating that substantially shields transmission of degradation products, leachants, and extractables from the substrate past and/or through the coating. Seals on a substrate can be applied to electronic circuitry to act as protection for the circuitry against, for example, moisture, dust, chemicals, and/or temperature extremes.
  • seals can be applied to devices to act as protection against, for example, moisture, dust, chemicals, leachants, extractable components (extractables) and/or degradation products, from passing from the device through the coating layer(s).
  • a seal therefore can be a one-way and/or two-way barrier to moisture, dust, chemicals, leachants, degradation products, and/or other material (fluid or gas), including biologic material.
  • the one-way barrier can be a barrier in either direction, a barrier to allowing material to contact the substrate, or a barrier to allowing material to pass from the substrate through the coating for example to the blood stream of a subject.
  • a medical device that is electrical in nature such as a pacemaker and/or another "active" implant body fluids in vivo can be substantially sealed by a coating and, thereby, substantially shielded from interacting with materials (fluids, gases, solids), in a manner that disrupts the substrate's intended functions and/or proper functioning, if any, or in a manner that has unintended consequences within and/or to the patient.
  • Medical devices that are not electrical in nature may also be sealed as provided herein.
  • substantially where used herein with respect to sealing or seals, can mean at least about one of 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5% 99.6%, 99.7%, 99.8%, 99.9%, 99.95%, 99.99%, and 99.995% sealed.
  • Substantially where used herein with respect to sealing or seals, can also or alternatively mean a seal that passes a coating visual inspection, an adhesion test, a chemical resistance test, and/or a coating fatigue test, device fatigue in an in vitro test, device fatigue in a simulated in vivo environment test, a resistance test in a simulated in vivo environment Examples of such tests include, but are not limited to, ASTM D ⁇ 677, ASTM D3359, ASTM D4541, ASTM D2197, ASTM D2370, ASTM D5179, ASTM D4145, ASTM 4146, ASTM Fl 854-01.
  • Polymer refers to a series of repeating monomeric units that have been cross-linked or polymerized. Any suitable polymer can be used to carry out the present invention. It is possible that the polymers of the invention may also comprise two, three, four or more different polymers. In some embodiments, of the invention only one polymer is used. In some preferred embodiments a combination of two polymers are used. Combinations of polymers can be in varying ratios, to provide coatings with differing properties. Those of skill in the art of polymer chemistry will be familiar with the different properties of polymeric compounds.
  • ploymers that may be used in the present invention include, but are not limited to polycarboxylic acids, cellulosic polymers, , proteins, polypeptides, polyvinylpyrrolidone, maleic anhydride polymers, polyamides, polyvinyl alcohols, polyethylene oxides, glycosaminoglycans, polysaccharides, polyesters, polyurethanes, polystyrenes, copolymers, silicones, polyorthoesters, polyanhydrides, copolymers of vinyl monomers, polycarbonates, polyethylenes, polypropytenes, polylactic acids, polyglycolic acids, polycaprolactones, polyhydroxybutyrate valerates, poiyacrylamides, polyethers, polyurethane dispersions, polyacryiates, acrylic latex dispersions, polyacrylic acid, mixtures and copolymers thereof.
  • the polymers of the present invention may be natural or synthetic in origin, including gelatin, chitosan, dextrin, cyclodextrin, Poly(urethanes), Poly(siloxanes) or silicones, Poly(acrylates) such as ⁇ oly(methyl methacrylate), poly(butyl methacrylate), and Poly(2-hydroxy ethyl methacrylate), Poly( vinyl alcohol) Poly(olefins) such as poly(ethylene), ⁇ oly(isoprene), halogenated polymers such as Poly(tetrafluoroethylene) - and derivatives and copolymers such as those commonly sold as Teflon® products, Poly(vinylidine fluoride), Poly(vinyl acetate), Poly(vinyl pyrrolidone),.
  • Suitable polymers also include absorbable and/or resorbable polymers including the following, combinations, copolymers and derivatives of the following: Polylactides (PLA), Polyglycolides (PGA), PolyOactide-co-glycolides) (PLGA), Polyanhydrides, Polyorthoesters, Poly(N-(2- hydroxypropyl) methacrylamide), Poly(l-aspartamide), etc.
  • Water-vapor trapping material as used herein includes, but is not limited to a hydrophilic polymer.
  • Water-vapor trapping material as used herein includes, but is not limited to a highly absorbent material, which may comprises a superabsorbent polymer.
  • water- vapor trapping materials include, but are not limited to, acrylate polymers, generally formed from acrylic acid, methacrylic acid, acrylate, methyl acrylate, ethyl acrylate, methyl methacrylate, ethyl methacrylate, a dialkylaminoalkyl acrylate, a dialkylaminoalkyl methacrylate, a trialkylammonioalkyl acrylate, and/or a trialkylammonioalkyl methacrylate, and include the polymers or copolymers of acrylic acid, methacrylic acid, methyl methacrylate, ethyl methacrylate, 2- dimethylaminoethyl methacrylate, and trimethylamraonioethyl methacrylate chloride.
  • acrylate polymers generally formed from acrylic acid, methacrylic acid, acrylate, methyl acrylate, ethyl acrylate, methyl methacrylate, ethyl
  • hydrophilic polymers include, but is not limited to poly(N-vinyI lactams), poly(N-vinyl acrylamides), ⁇ oly(N- alkylacrylamides), substituted and unsubstituted acrylic and methacrylic acid polymers, polyvinyl alcohol (PVA), polyvinylamine, copolymers thereof and copolymers with other types of hydrophilic monomers (e.g.
  • polysaccharides examples include hydrogels.
  • Copolymers of any of the water-vapor trapping materials mentioned herein, and blends thereof may also be used.
  • "Hydrophobic polymer” as used herein can refer to any polymer resistant to wetting, or not readily wet, by water, i.e., having a lack of affinity for water.
  • hydrophobic polymers include, by way of illustration only, polyolefins, such as polyethylene, poly(isobutene), ⁇ oly(isoprene), poly(4-methyl-l- ⁇ entene), polypropylene, ethylene-propylene copolymers, ethylene-propylene-hexadiene copolymers, and ethylene-vinyl acetate copolymers; metallocene polyolefins, such as ethylene-butene copolymers and ethyiene-octene copolymers; styrene polymers, such as poly(styrene), poly(2-methylsiyrene), and styrene-acrylonitrile copolymers having less than about 20 mole-percent acrylonitrile; vinyl polymers, such as ⁇ oly( vinyl butyrate), poly( vinyl decanoate), poly(vinyl dodecanoate), poly( vinyl hexadecanoate), poly(
  • Copolymers of any of the hydrophobic polymers mentioned herein, and blends thereof may also be used.
  • the hydrophobic polymer also may contain minor amounts of additives as is customary in the art.
  • the hydrophobic polymer may contain pigments, delustrants, antioxidants, antistatic agents, stabilizers, oxygen scavengers, and the like.
  • the hydrophobic polymer is a polymer having a bulk density of at least about 1.00 grams per cubic centimeter (g/cc). In some embodiments, the hydrophobic polymer is a polymer having a bulk density of greater than about 1.00 gram per cubic centimeter (g/cc).
  • the hydrophobic polymer is a polymer having a bulk density of one of at least about 1.01 , 1.02, 1.03, 1.05, 1.06, 1.07, 1.08, 1.09, 2.00, 2.01, 2.02, 2.03, 2.04, 2.05, 2.06, 2.07, 2.08, 2.09, 2.10, 2.11, 2.12, 2.13, 2.14, 2.15, 2.16, 2.17, 2.18, 2.19, 2.20, 2.21, 2.22, 2.23, 2.24, 2.25, 2.26, 2.27, 2.28, 2.29, 2.30, 2.31, 2.32, 2.33, 2.34, 2.35, 2.36, 2.37, 2,38, 2.39, 2.40 grams per cubic centimeter (g/cc).
  • Polyolefin as used herein can refer to a polymer prepared by the addition polymerization of one or more unsaturated monomers which contain only carbon and hydrogen atoms.
  • examples of such polyolefins include polyethylene, polypropylene, poly(I-butene), poly(2-butene), poly(l-pentene), poly(2-pentene), poly(3- methyl-1-pentene), poly(4-methyl-l-pentene), and the like.
  • such term is meant to include blends of two or more polyolefins and random and block copolymers prepared from two or more different unsaturated monomers.
  • Compressed fluid refers to a fluid of appreciable density (e.g., >0.2 g/cc) that is a gas at standard temperature and pressure.
  • Supercritical fluid refers to a compressed fluid under conditions wherein the temperature is at least 80% of the critical temperature of the fluid and the pressure is at least 50% of the critical pressure of the fluid.
  • Examples of substances that demonstrate supercritical or near critical behavior suitable for the present invention include, but are not limited to carbon dioxide, isobutylene, ammonia, water, methanol, ethanol, ethane, propane, butane, pentane, dimethyl ether, xenon, sulfur hexafluoride, halogenated and partially halogenated materials such as chlorofluorocarbons, hydrochlorofluorocarbons, hydrofluorocarbons, perfluorocarbons (such as perfluoromethane and perfuoropropane, chloroform, trichloro-fluoromethane, dichloro-difluoromethane, dichloro-tetrafluoroethane), 1,1,1,2,3,3-hexafluoo ⁇ ro ⁇ ane (R236ea) and mixtures thereof.
  • chlorofluorocarbons such as perfluoromethane and perfuoropropane, chloroform, trichloro-flu
  • Intering refers to the process by which the co-deposited impermeable dispersed solid- polymer matrix, as described herein, or the hydrophobic polymer and water-vapor-trapping material becomes fused and adherent to the substrate by treatment of the coated substrate with a compressed gas, compressed liquid, or supercritical fluid that is a non-solvent for both the polymer and the impermeable dispersed solid or the hydrophobic polymer and water-vapor-trapping material, but a plasticizing agent for the polymer(s).
  • Rapid Expansion of Supercritical Solutions involves the dissolution of a polymer into a compressed fluid, typically supercritical CO 2 , followed by rapid expansion into a chamber at atmospheric pressure.
  • Solution Enhanced Dispersion of Supercritical Solutions involves a spray process for the generation of polymer particles, which are formed when a compressed fluid (e.g. supercritical fluid, preferably supercritical CO 2 ) is used as a diluent to a vehicle in which a polymer dissolved, (one that can dissolve both the polymer and the compressed gas).
  • a compressed fluid e.g. supercritical fluid, preferably supercritical CO 2
  • the mixing of the compressed fluid diluent with the polymer-containing solution may be achieved by encounter of a first stream containing the polymer solution and a second stream containing the diluent compressed fluid, for example, within one spray nozzle or by the use of multiple spray nozzles.
  • the solvent in the polymer solution may be one compound or a mixture of two or more ingredients and may be or comprise an alcohol (including diols, triols, etc.), ether, amine, ketone, carbonate, or alkanes, or hydrocarbon (aliphatic or aromatic) or may be a mixture of compounds, such as mixtures of alkanes, or mixtures of one or more alkanes in combination with additional compounds such as one or more alcohols, (e.g., from 0 or 0.1 to 5% of a Ci to Ci 5 alcohol, including diols, triols, etc.). See for example US Patent No. 6,669,785.
  • the solvent may optionally contain a surfactant, as also described in (for example) US Patent No.
  • a first stream of fluid comprising a polymer dissolved in a common solvent is co-sprayed with a second stream of compressed fluid.
  • Polymer particles are produced as the second stream acts as a diluent that weakens the solvent in the polymer solution of the first stream.
  • the now combined streams of fluid, along with the polymer particles, flow out of the nozzle assembly into a collection vessel. Control of particle size, particle size distribution, and morphology is achieved by tailoring the following process variables: temperature, pressure, solvent composition of the first stream, flow-rate of the first stream, flow-rate of the second stream, composition of the second stream (where soluble additives may be added to the compressed gas), and conditions of the capture vessel.
  • the capture vessel contains a fluid phase that is at least five to ten times (5-1Ox) atmospheric pressure.
  • Electrostatic Rapid Expansion of Supercritical Solutions or “e-RESS” or “eRESS” as used herein refers to Electrostatic Capture as described herein combined with Rapid Expansion of Supercritical Solutions as described herein.
  • Electrostatic Solution Enhanced Dispersion of Supercritical Solutions or "e-SEDS” or “eSEDS” as used herein, refers to Electrostatic Capture as described herein combined with Solution Enhanced Dispersion of Supercritical Solutions as described herein.
  • Electrostatic Dry Powder Coating or "e-DPC” or “eDPC” as used herein refers to Electrostatic Capture as described herein combined with Dry Powder Coating.
  • e-DPC deposits material (including, for example, polymer or impermeable dispersed solid) on the device or other substrate as dry powder, using electrostatic capture to attract the powder particles to the substrate.
  • Dry powder spraying (“Dry Powder
  • Open vessel refers to a vessel open to the outside atmosphere, and thus at substantially the same temperature and pressure as the outside atmosphere.
  • “Closed vessel” as used herein refers to a vessel sealed from the outside atmosphere, and thus may be at significantly different temperatures and pressures to the outside atmosphere. Examples
  • a biocompatible fluoropolymer or other hydrophobic biocompatible polymer is dissolved in an appropriate supercritical solvent such as carbon dioxide.
  • This solution is maintained in a syringe pump or other pressure vessel and transferred to a spraying vessel that is maintained above the compressed gas's critical pressure and temperature as modified by the solute.
  • the device or other substrate to be coated is held such that it can placed at an electrical potential relative to a nozzle through which the compressed gas solution is to be sprayed (10 kV, for example, with the device held at 5 kV and the nozzle held at -5kV).
  • the electrical field between the device and the nozzle is designed to be homogenous and constant.
  • the polymer solution is expanded through the restrictor nozzle by electrostatic rapid expansion of a supercritical solution (e-RESS), thereby coating the device with a fine film controllable in both thickness and conformality. Subsequent processing in the gas in its uncompressed state further reduces the volume of the film increasing its conformality.
  • e-RESS supercritical solution
  • a second layer is deposited consisting of a silicon based polymer in the same manner as the first polymer layer.
  • this polymer could be deposited as a dry dispersed solid using e-DPC or from solution in a compressed gas solvent. This silicon based polymer is selected so that it traps any water vapor that permeates the fluoropolymer layer.
  • a biocompatible fluoropolymer or other hydrophobic biocompatible polymer is dissolved in an appropriate supercritical solvent such as carbon dioxide.
  • This solution is maintained in a syringe pump or other pressure vessel and transferred to a spraying vessel that is maintained above the compressed gas's critical pressure and temperature as modified by the solute.
  • the device or other substrate to be coated is held such that it can placed at an electrical potential relative to a nozzle through which the compressed gas solution is to be sprayed (10 kV, for example, with the device held at 5 IcV and the nozzle held at -5kV).
  • the electrical field between the device and the nozzle is designed to be homogenous and constant.
  • the polymer solution is expanded through the restrictor nozzle by electrostatic rapid expansion of a supercritical solution (e-RESS), thereby coating the device with a fine film controllable in both thickness and conformality. Subsequent processing in the gas in its uncompressed state further reduces the volume of the film increasing its conformality.
  • a second layer of carbonaceous material is deposited by e-DPC.
  • a quantity of carbonaceous material is loaded as a plug into a chamber. The quantity of material initially loaded is dependent upon the desired coating mass and is a function of the potential at which the device or other substrate is held and the backpressure placed on the plug.
  • a valve is rapidly opened through which the material expands creating an aerosolized cloud which coats the device or other substrate as a dry powder. This coating is immediately followed with a second fluoropolymer coating and undergoes the same volume reducing process as the initial layer (processing in the gas in its uncompressed state to further reduce the volume of the film and increase its conformality).

Abstract

La présente invention concerne le dépôt d'un revêtement comprenant un solide polymère et imperméable dispersé sur un substrat selon les étapes suivantes : le déchargement d'au moins un solide imperméable dispersé sous forme de poudre sèche à travers un premier orifice; le déchargement d'au moins un polymère sous forme de poudre sèche à travers un second orifice; la déposition du polymère et/ou des particules solides imperméables dispersées sur ladite surface, durant laquelle un potentiel électrique est maintenu entre le substrat et les particules et/ou les polymères solides imperméables dispersés, formant ainsi le revêtement; et la soudure dudit revêtement sous des conditions qui ne perturbent pas l'activité et/ou la fonction du substrat. Un procédé similaire est prévu pour la déposition d'un revêtement comprenant un polymère hydrophobique et un matériel de piégeage de vapeur d'eau sur un substrat.
PCT/US2008/064732 2007-05-25 2008-05-23 Films de polymères pour le revêtement des dispositifs médicaux WO2008148013A1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EP08756215.3A EP2170418B1 (fr) 2007-05-25 2008-05-23 Films de polymères pour le revêtement des dispositifs médicaux
JP2010510441A JP2010527746A (ja) 2007-05-25 2008-05-23 メディカルデバイスコーティング用ポリマーフィルム
CA2688314A CA2688314C (fr) 2007-05-25 2008-05-23 Films de polymeres pour le revetement des dispositifs medicaux
AU2008256684A AU2008256684B2 (en) 2007-05-25 2008-05-23 Polymer films for medical device coating
CN200880100102.3A CN101815540B (zh) 2007-05-25 2008-05-23 用于医疗器材涂层的聚合物膜
US12/601,101 US8900651B2 (en) 2007-05-25 2008-12-04 Polymer films for medical device coating
IL202321A IL202321A (en) 2007-05-25 2009-11-25 Polymer layers for medical device coating

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US94036507P 2007-05-25 2007-05-25
US60/940,365 2007-05-25
US97937507P 2007-10-11 2007-10-11
US60/979,375 2007-10-11

Publications (1)

Publication Number Publication Date
WO2008148013A1 true WO2008148013A1 (fr) 2008-12-04

Family

ID=40075522

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/064732 WO2008148013A1 (fr) 2007-05-25 2008-05-23 Films de polymères pour le revêtement des dispositifs médicaux

Country Status (8)

Country Link
US (1) US8900651B2 (fr)
EP (1) EP2170418B1 (fr)
JP (1) JP2010527746A (fr)
CN (1) CN101815540B (fr)
AU (2) AU2008256684B2 (fr)
CA (1) CA2688314C (fr)
IL (1) IL202321A (fr)
WO (1) WO2008148013A1 (fr)

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010009335A1 (fr) 2008-07-17 2010-01-21 Micell Technologies, Inc. Dispositif médical d’administration de médicament
WO2010111232A2 (fr) 2009-03-23 2010-09-30 Micell Technologies, Inc. Dispositif médical d'administration de médicament
US8017074B2 (en) 2004-01-07 2011-09-13 Noxilizer, Inc. Sterilization system and device
WO2011136882A1 (fr) * 2010-04-29 2011-11-03 Medtronic Vascular Inc. Système et procédé de fabrication d'une endoprothèse
WO2012009684A2 (fr) 2010-07-16 2012-01-19 Micell Technologies, Inc. Dispositif médical d'administration de médicament
CN102481195A (zh) * 2009-04-01 2012-05-30 米歇尔技术公司 涂覆支架
WO2012092504A2 (fr) 2010-12-30 2012-07-05 Micell Technologies, Inc. Nanoparticules et revêtements particulaires modifiés en surface, ballonnets revêtus et procédés associés
US8425837B2 (en) 2009-02-23 2013-04-23 Noxilizer, Inc. Device and method for gas sterilization
WO2013059509A1 (fr) 2011-10-18 2013-04-25 Micell Technologies, Inc. Dispositif médical d'administration de médicament
US8703066B2 (en) 2004-01-07 2014-04-22 Noxilizer, Inc. Sterilization system and method
US8758429B2 (en) 2005-07-15 2014-06-24 Micell Technologies, Inc. Polymer coatings containing drug powder of controlled morphology
US8795762B2 (en) 2010-03-26 2014-08-05 Battelle Memorial Institute System and method for enhanced electrostatic deposition and surface coatings
US8834913B2 (en) 2008-12-26 2014-09-16 Battelle Memorial Institute Medical implants and methods of making medical implants
US8852625B2 (en) 2006-04-26 2014-10-07 Micell Technologies, Inc. Coatings containing multiple drugs
US8900651B2 (en) 2007-05-25 2014-12-02 Micell Technologies, Inc. Polymer films for medical device coating
US9433516B2 (en) 2007-04-17 2016-09-06 Micell Technologies, Inc. Stents having controlled elution
US9510856B2 (en) 2008-07-17 2016-12-06 Micell Technologies, Inc. Drug delivery medical device
US9539593B2 (en) 2006-10-23 2017-01-10 Micell Technologies, Inc. Holder for electrically charging a substrate during coating
US9636309B2 (en) 2010-09-09 2017-05-02 Micell Technologies, Inc. Macrolide dosage forms
US9737642B2 (en) 2007-01-08 2017-08-22 Micell Technologies, Inc. Stents having biodegradable layers
US9789233B2 (en) 2008-04-17 2017-10-17 Micell Technologies, Inc. Stents having bioabsorbable layers
US10117972B2 (en) 2011-07-15 2018-11-06 Micell Technologies, Inc. Drug delivery medical device
US10188772B2 (en) 2011-10-18 2019-01-29 Micell Technologies, Inc. Drug delivery medical device
US10232092B2 (en) 2010-04-22 2019-03-19 Micell Technologies, Inc. Stents and other devices having extracellular matrix coating
US10272606B2 (en) 2013-05-15 2019-04-30 Micell Technologies, Inc. Bioabsorbable biomedical implants
US10464100B2 (en) 2011-05-31 2019-11-05 Micell Technologies, Inc. System and process for formation of a time-released, drug-eluting transferable coating
US10835396B2 (en) 2005-07-15 2020-11-17 Micell Technologies, Inc. Stent with polymer coating containing amorphous rapamycin
US11039943B2 (en) 2013-03-12 2021-06-22 Micell Technologies, Inc. Bioabsorbable biomedical implants
US20210282947A1 (en) * 2017-12-14 2021-09-16 Boston Scientific Scimed, Inc. Stent including an expandable member
US11369498B2 (en) 2010-02-02 2022-06-28 MT Acquisition Holdings LLC Stent and stent delivery system with improved deliverability
US11426494B2 (en) 2007-01-08 2022-08-30 MT Acquisition Holdings LLC Stents having biodegradable layers

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8458879B2 (en) * 2001-07-03 2013-06-11 Advanced Bio Prosthetic Surfaces, Ltd., A Wholly Owned Subsidiary Of Palmaz Scientific, Inc. Method of fabricating an implantable medical device
US20090269480A1 (en) * 2008-04-24 2009-10-29 Medtronic Vascular, Inc. Supercritical Fluid Loading of Porous Medical Devices With Bioactive Agents
JP2010251745A (ja) 2009-04-10 2010-11-04 Asml Netherlands Bv 液浸リソグラフィ装置及びデバイス製造方法
US10238776B2 (en) 2010-12-29 2019-03-26 St. Jude Medical, Atrial Fibrillation Division, Inc. Hydrophobic catheter and composition
US20130255061A1 (en) * 2012-04-03 2013-10-03 Becton, Dickinson And Company Systems and methods for applying a novel antimicrobial coating material to a medical device
US9913933B2 (en) 2013-03-15 2018-03-13 St. Jude Medical, Cardiology Division, Inc. Multilayered catheter shaft containing polyvinylidene fluoride polymers
CN103272280A (zh) * 2013-05-24 2013-09-04 南京大学医学院附属鼓楼医院 一种对脱细胞血管支架或人造血管改性的方法
US9345897B2 (en) * 2014-02-21 2016-05-24 Boston Scientific Neuromodulation Corporation Multi-layer covering for control modules of electrical implantable medical devices and methods of making and using
US10588732B2 (en) 2014-03-07 2020-03-17 IconLab USA, Inc. Multipurpose implant with modeled surface structure for soft tissue reconstruction
RU2699811C1 (ru) 2014-03-07 2019-09-11 Айконлаб Инк. Многоцелевой имплантат с заданной структурой поверхности для реконструкции мягких тканей
US11406742B2 (en) 2014-07-18 2022-08-09 M.A. Med Alliance SA Coating for intraluminal expandable catheter providing contact transfer of drug micro-reservoirs
JP6154370B2 (ja) * 2014-12-26 2017-06-28 住友ゴム工業株式会社 表面改質金属及び金属表面の改質方法
JP2018526409A (ja) 2015-09-09 2018-09-13 マイセル・テクノロジーズ，インコーポレイテッド Ｍｉｃｅｌｌ技術のバイオ医薬品への適用
US10687642B2 (en) 2016-02-05 2020-06-23 Havi Global Solutions, Llc Microstructured packaging surfaces for enhanced grip
CN108778681B (zh) 2016-02-05 2020-08-28 哈维全球解决方案有限责任公司 具有改进的隔热和冷凝抗性的微结构化表面
RU2747970C1 (ru) 2016-04-07 2021-05-18 Хави Глобал Солюшенз, Ллк Пакет для текучей среды, имеющий внутреннюю микроструктуру
CN109279180B (zh) * 2017-07-21 2020-06-16 深圳市中科先见医疗科技有限公司 一种具有封装层的医学植入器件以及一种医学植入器件的封装方法
CN109626319A (zh) * 2019-01-11 2019-04-16 清华大学 一种植入式器件及其封装方法
US10995233B2 (en) 2019-08-02 2021-05-04 Building Materials Investment Corporation Water-resistant acrylic coatings
KR102297774B1 (ko) * 2021-02-09 2021-09-03 (주)테라시스 분말 스프레이 방식을 이용한 기능성 시트 및 이의 제조 방법

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030031699A1 (en) * 2002-09-30 2003-02-13 Medtronic Minimed, Inc. Polymer compositions containing bioactive agents and methods for their use
US6524698B1 (en) * 1990-09-27 2003-02-25 Helmuth Schmoock Fluid impermeable foil
US20030143315A1 (en) * 2001-05-16 2003-07-31 Pui David Y H Coating medical devices
US6627246B2 (en) * 2000-05-16 2003-09-30 Ortho-Mcneil Pharmaceutical, Inc. Process for coating stents and other medical devices using super-critical carbon dioxide
US20030222018A1 (en) 2002-05-28 2003-12-04 Battelle Memorial Institute Methods for producing films using supercritical fluid
WO2003101624A1 (fr) 2002-05-28 2003-12-11 Battelle Memorial Institute Depot electrostatique de particules issues de l'expansion rapide de solutions fluides supercritiques
US20050003074A1 (en) * 1996-11-13 2005-01-06 Phoqus Pharmaceuticals Limited Method and apparatus for the coating of substrates for pharmaceutical use
US20050196424A1 (en) * 2003-05-02 2005-09-08 Chappa Ralph A. Medical devices and methods for producing the same
US20060121089A1 (en) * 2002-03-20 2006-06-08 Advanced Cardiovascular Systems, Inc. Coatings for implantable medical devices
US7201940B1 (en) * 2001-06-12 2007-04-10 Advanced Cardiovascular Systems, Inc. Method and apparatus for thermal spray processing of medical devices

Family Cites Families (379)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3123077A (en) 1964-03-03 Surgical suture
US3087860A (en) 1958-12-19 1963-04-30 Abbott Lab Method of prolonging release of drug from a precompressed solid carrier
US3087660A (en) 1962-07-24 1963-04-30 Yankee Plasties Inc Two-step garment hanger
US3457280A (en) 1967-06-12 1969-07-22 American Cyanamid Co Alpha-glycolide and methods for the isolation thereof
US3597449A (en) 1967-11-16 1971-08-03 American Cyanamid Co Stable glycolide and lactide composition
ZA737247B (en) 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US4000137A (en) 1975-06-10 1976-12-28 American Home Products Corporation Antitumor derivatives of periodate-oxidized nucleosides
US4285987A (en) * 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4326532A (en) 1980-10-06 1982-04-27 Minnesota Mining And Manufacturing Company Antithrombogenic articles
SE445884B (sv) 1982-04-30 1986-07-28 Medinvent Sa Anordning for implantation av en rorformig protes
US4734451A (en) 1983-09-01 1988-03-29 Battelle Memorial Institute Supercritical fluid molecular spray thin films and fine powders
US4582731A (en) 1983-09-01 1986-04-15 Battelle Memorial Institute Supercritical fluid molecular spray film deposition and powder formation
US4734227A (en) 1983-09-01 1988-03-29 Battelle Memorial Institute Method of making supercritical fluid molecular spray films, powder and fibers
US6309669B1 (en) 1984-03-16 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
US4733665C2 (en) 1985-11-07 2002-01-29 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
JPH0698902B2 (ja) 1986-01-30 1994-12-07 マツダ株式会社 車両の伝達トルク制御装置
US4985625A (en) 1986-03-06 1991-01-15 Finnigan Corporation Transfer line for mass spectrometer apparatus
US5106650A (en) 1988-07-14 1992-04-21 Union Carbide Chemicals & Plastics Technology Corporation Electrostatic liquid spray application of coating with supercritical fluids as diluents and spraying from an orifice
ATE96059T1 (de) * 1988-07-14 1993-11-15 Union Carbide Corp Elektrostatisches aufspruehen von ueberzuegen aus einer duese unter verwendung einer superkritischen fluessigkeit als verduenner.
US4950239A (en) 1988-08-09 1990-08-21 Worldwide Medical Plastics Inc. Angioplasty balloons and balloon catheters
WO1990001969A1 (fr) 1988-08-24 1990-03-08 Slepian Marvin J Etancheification a l'aide d'un polymere biodegradable de la surface interieure d'une lumiere d'un organe
US4931037A (en) 1988-10-13 1990-06-05 International Medical, Inc. In-dwelling ureteral stent and injection stent assembly, and method of using same
US4958625A (en) 1989-07-18 1990-09-25 Boston Scientific Corporation Biopsy needle instrument
DE69002295T2 (de) 1989-09-25 1993-11-04 Schneider Usa Inc Mehrschichtextrusion als verfahren zur herstellung von ballons zur gefaessplastik.
US5000519A (en) 1989-11-24 1991-03-19 John Moore Towed vehicle emergency brake control system
US5674192A (en) 1990-12-28 1997-10-07 Boston Scientific Corporation Drug delivery
JP2641781B2 (ja) 1990-02-23 1997-08-20 シャープ株式会社 半導体素子分離領域の形成方法
AU7998091A (en) 1990-05-17 1991-12-10 Harbor Medical Devices, Inc. Medical device polymer
US5090419A (en) 1990-08-23 1992-02-25 Aubrey Palestrant Apparatus for acquiring soft tissue biopsy specimens
US6248129B1 (en) 1990-09-14 2001-06-19 Quanam Medical Corporation Expandable polymeric stent with memory and delivery apparatus and method
GB2253164B (en) 1991-02-22 1994-10-05 Hoechst Uk Ltd Improvements in or relating to electrostatic coating of substrates of medicinal products
US5158986A (en) 1991-04-05 1992-10-27 Massachusetts Institute Of Technology Microcellular thermoplastic foamed with supercritical fluid
US5195969A (en) 1991-04-26 1993-03-23 Boston Scientific Corporation Co-extruded medical balloons and catheter using such balloons
US5372676A (en) * 1991-05-15 1994-12-13 Lowe; Michael Method for producing replicated paving stone
US5356433A (en) 1991-08-13 1994-10-18 Cordis Corporation Biocompatible metal surfaces
US5243023A (en) 1991-08-28 1993-09-07 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Polyimides containing amide and perfluoroisopropylidene connecting groups
US5366504A (en) 1992-05-20 1994-11-22 Boston Scientific Corporation Tubular medical prosthesis
JPH0698902A (ja) * 1991-11-22 1994-04-12 Janome Sewing Mach Co Ltd 骨インプラントの製造方法
US5697882A (en) 1992-01-07 1997-12-16 Arthrocare Corporation System and method for electrosurgical cutting and ablation
JPH07505316A (ja) 1992-03-31 1995-06-15 ボストン　サイエンティフィック　コーポレーション 医療用ワイヤ
US5288711A (en) 1992-04-28 1994-02-22 American Home Products Corporation Method of treating hyperproliferative vascular disease
US5342621A (en) 1992-09-15 1994-08-30 Advanced Cardiovascular Systems, Inc. Antithrombogenic surface
US5500180A (en) 1992-09-30 1996-03-19 C. R. Bard, Inc. Method of making a distensible dilatation balloon using a block copolymer
US5385776A (en) * 1992-11-16 1995-01-31 Alliedsignal Inc. Nanocomposites of gamma phase polymers containing inorganic particulate material
EP0604022A1 (fr) 1992-12-22 1994-06-29 Advanced Cardiovascular Systems, Inc. Endoprothèse résorbable, à plusieurs couches, pour le maintien des vaisseaux, et sa méthode de fabrication
US5324049A (en) 1992-12-23 1994-06-28 Xerox Corporation Mandrel with flared, dish shaped disk and process for using mandrel
WO1994016646A1 (fr) 1993-01-19 1994-08-04 Schneider (Usa) Inc. Extenseur en materiau composite avec gainage
US5340614A (en) 1993-02-11 1994-08-23 Minnesota Mining And Manufacturing Company Methods of polymer impregnation
US6228879B1 (en) 1997-10-16 2001-05-08 The Children's Medical Center Methods and compositions for inhibition of angiogenesis
JPH08507715A (ja) 1993-03-18 1996-08-20 シーダーズ サイナイ メディカル センター 生体人工部材のための薬剤導入性および放出性重合性コーティング
US20020055710A1 (en) 1998-04-30 2002-05-09 Ronald J. Tuch Medical device for delivering a therapeutic agent and method of preparation
US5403347A (en) 1993-05-27 1995-04-04 United States Surgical Corporation Absorbable block copolymers and surgical articles fabricated therefrom
US5350627A (en) 1993-06-11 1994-09-27 Camelot Technologies, Inc. Coated webs
US5380299A (en) 1993-08-30 1995-01-10 Med Institute, Inc. Thrombolytic treated intravascular medical device
US5350361A (en) 1993-11-10 1994-09-27 Medtronic, Inc. Tri-fold balloon for dilatation catheter and related method
US5494620A (en) 1993-11-24 1996-02-27 United States Surgical Corporation Method of manufacturing a monofilament suture
US5626611A (en) 1994-02-10 1997-05-06 United States Surgical Corporation Composite bioabsorbable materials and surgical articles made therefrom
US6146356A (en) 1994-03-02 2000-11-14 Scimed Life Systems, Inc. Block copolymer elastomer catheter balloons
PT748232E (pt) 1994-03-02 2000-07-31 Scimed Life Systems Inc Baloes de cateter em elastomero de copolimero de blocos
WO1996001874A1 (fr) * 1994-07-12 1996-01-25 Berwind Pharmaceutical Services, Inc. Composition d'enrobage constituant une pellicule de protection contre l'humidite, procede et forme enrobee
US5626862A (en) 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
JPH10511957A (ja) 1995-01-05 1998-11-17 ザ ボード オブ リージェンツ オブ ザ ユニヴァーシティ オブ ミシガン 表面改質ナノ微粒子並びにその製造及び使用方法
US6231600B1 (en) 1995-02-22 2001-05-15 Scimed Life Systems, Inc. Stents with hybrid coating for medical devices
US6120536A (en) 1995-04-19 2000-09-19 Schneider (Usa) Inc. Medical devices with long term non-thrombogenic coatings
US5837313A (en) 1995-04-19 1998-11-17 Schneider (Usa) Inc Drug release stent coating process
US20020091433A1 (en) 1995-04-19 2002-07-11 Ni Ding Drug release coated stent
WO1996034634A1 (fr) 1995-05-01 1996-11-07 Sam Yang Co. Ltd. Membrane bioresorbable implantable et son procede de preparation
US5714007A (en) 1995-06-06 1998-02-03 David Sarnoff Research Center, Inc. Apparatus for electrostatically depositing a medicament powder upon predefined regions of a substrate
US5674242A (en) 1995-06-06 1997-10-07 Quanam Medical Corporation Endoprosthetic device with therapeutic compound
US5609629A (en) 1995-06-07 1997-03-11 Med Institute, Inc. Coated implantable medical device
CA2178541C (fr) 1995-06-07 2009-11-24 Neal E. Fearnot Dispositif medical implantable
US6256529B1 (en) 1995-07-26 2001-07-03 Burdette Medical Systems, Inc. Virtual reality 3D visualization for surgical procedures
JP3476604B2 (ja) 1995-08-22 2003-12-10 鐘淵化学工業株式会社 薬剤を付着・コーティングしたステントの製造方法
DE69600289T2 (de) 1995-09-19 1998-09-03 Mitsubishi Gas Chemical Co Biologisch abbaubares wasserlösliches Polymer
US6461644B1 (en) 1996-03-25 2002-10-08 Richard R. Jackson Anesthetizing plastics, drug delivery plastics, and related medical products, systems and methods
CN1171966C (zh) 1996-05-31 2004-10-20 东陶机器株式会社 防污性构件及防污涂层组合物
US6143037A (en) 1996-06-12 2000-11-07 The Regents Of The University Of Michigan Compositions and methods for coating medical devices
US5876426A (en) 1996-06-13 1999-03-02 Scimed Life Systems, Inc. System and method of providing a blood-free interface for intravascular light delivery
FR2750897B1 (fr) 1996-07-10 1998-09-18 Sames Sa Projecteur triboelectrique, installation de projection de produit de revetement et procede de commande d'un tel projecteur
US6013855A (en) 1996-08-06 2000-01-11 United States Surgical Grafting of biocompatible hydrophilic polymers onto inorganic and metal surfaces
US6884377B1 (en) 1996-08-27 2005-04-26 Trexel, Inc. Method and apparatus for microcellular polymer extrusion
US6193963B1 (en) 1996-10-17 2001-02-27 The Regents Of The University Of California Method of treating tumor-bearing patients with human plasma hyaluronidase
US6387121B1 (en) 1996-10-21 2002-05-14 Inflow Dynamics Inc. Vascular and endoluminal stents with improved coatings
ZA9711732B (en) 1996-12-31 1998-12-28 Quadrant Holdings Cambridge Methods and compositions for improvement bioavailability of bioactive agents for mucosal delivery
US6884823B1 (en) 1997-01-16 2005-04-26 Trexel, Inc. Injection molding of polymeric material
US6273913B1 (en) 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
GB9800936D0 (en) 1997-05-10 1998-03-11 Univ Nottingham Biofunctional polymers
US6416779B1 (en) 1997-06-11 2002-07-09 Umd, Inc. Device and method for intravaginal or transvaginal treatment of fungal, bacterial, viral or parasitic infections
US6433154B1 (en) 1997-06-12 2002-08-13 Bristol-Myers Squibb Company Functional receptor/kinase chimera in yeast cells
US6077880A (en) 1997-08-08 2000-06-20 Cordis Corporation Highly radiopaque polyolefins and method for making the same
KR100559192B1 (ko) 1997-08-28 2006-03-13 닛산 가가쿠 고교 가부시키 가이샤 혈관신생 촉진제 및 혈관신생 작용증강제
US7378105B2 (en) 1997-09-26 2008-05-27 Abbott Laboratories Drug delivery systems, kits, and methods for administering zotarolimus and paclitaxel to blood vessel lumens
US6127000A (en) 1997-10-10 2000-10-03 North Carolina State University Method and compositions for protecting civil infrastructure
IES81060B2 (en) 1997-11-07 2000-01-12 Salviac Ltd An embolic protection device
DE59808721D1 (de) 1997-11-24 2003-07-17 Efmt Entwicklungs Und Forschun Verfahren zur immobilisierung von mediatormolekülen auf anorganischen und metallischen implantatmaterialien
US5957975A (en) 1997-12-15 1999-09-28 The Cleveland Clinic Foundation Stent having a programmed pattern of in vivo degradation
US6129755A (en) 1998-01-09 2000-10-10 Nitinol Development Corporation Intravascular stent having an improved strut configuration
US7208010B2 (en) 2000-10-16 2007-04-24 Conor Medsystems, Inc. Expandable medical device for delivery of beneficial agent
SE9801288D0 (sv) 1998-04-14 1998-04-14 Astra Ab Vaccine delivery system and metod of production
US8029561B1 (en) 2000-05-12 2011-10-04 Cordis Corporation Drug combination useful for prevention of restenosis
GB9808052D0 (en) 1998-04-17 1998-06-17 Secr Defence Implants for administering substances and methods of producing implants
US6206914B1 (en) 1998-04-30 2001-03-27 Medtronic, Inc. Implantable system with drug-eluting cells for on-demand local drug delivery
US6190699B1 (en) 1998-05-08 2001-02-20 Nzl Corporation Method of incorporating proteins or peptides into a matrix and administration thereof through mucosa
FR2780057B1 (fr) 1998-06-18 2002-09-13 Sanofi Sa Phenoxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant
KR20010083057A (ko) 1998-06-19 2001-08-31 추후제출 항-감염 및 피임성을 갖는 의료 장치
US6153252A (en) 1998-06-30 2000-11-28 Ethicon, Inc. Process for coating stents
US6541033B1 (en) 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
US8070796B2 (en) 1998-07-27 2011-12-06 Icon Interventional Systems, Inc. Thrombosis inhibiting graft
US7004962B2 (en) 1998-07-27 2006-02-28 Schneider (Usa), Inc. Neuroaneurysm occlusion and delivery device and method of using same
US6248127B1 (en) 1998-08-21 2001-06-19 Medtronic Ave, Inc. Thromboresistant coated medical device
US6342062B1 (en) 1998-09-24 2002-01-29 Scimed Life Systems, Inc. Retrieval devices for vena cava filter
US6245104B1 (en) 1999-02-28 2001-06-12 Inflow Dynamics Inc. Method of fabricating a biocompatible stent
US6143314A (en) 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
US6355691B1 (en) 1998-11-12 2002-03-12 Tobias M. Goodman Urushiol therapy of transitional cell carcinoma of the bladder
ATE269114T1 (de) 1998-11-20 2004-07-15 Univ Connecticut Verfahren und vorrichtung zur steuerung der gewebeimplantat-interaktionen
US6372246B1 (en) 1998-12-16 2002-04-16 Ortho-Mcneil Pharmaceutical, Inc. Polyethylene glycol coating for electrostatic dry deposition of pharmaceuticals
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6706283B1 (en) 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
SE9900519D0 (sv) 1999-02-17 1999-02-17 Lars Lidgren A method for the preparation of UHMWPE doped with an antioxidant and an implant made thereof
US6171327B1 (en) 1999-02-24 2001-01-09 Scimed Life Systems, Inc. Intravascular filter and method
US6620192B1 (en) 1999-03-16 2003-09-16 Advanced Cardiovascular Systems, Inc. Multilayer stent
SE9901002D0 (sv) 1999-03-19 1999-03-19 Electrolux Ab Anordning för rengöring av textilföremål med en förtätad vätskeformig behandlingsgas
US6364903B2 (en) 1999-03-19 2002-04-02 Meadox Medicals, Inc. Polymer coated stent
US6368658B1 (en) 1999-04-19 2002-04-09 Scimed Life Systems, Inc. Coating medical devices using air suspension
US6923979B2 (en) 1999-04-27 2005-08-02 Microdose Technologies, Inc. Method for depositing particles onto a substrate using an alternating electric field
US8016873B1 (en) 1999-05-03 2011-09-13 Drasler William J Intravascular hinge stent
US6726712B1 (en) 1999-05-14 2004-04-27 Boston Scientific Scimed Prosthesis deployment device with translucent distal end
US6815218B1 (en) 1999-06-09 2004-11-09 Massachusetts Institute Of Technology Methods for manufacturing bioelectronic devices
DK1196163T3 (da) 1999-07-06 2010-03-29 Endorech Inc Farmaceutiske sammensætninger til behandling af insulinresistens
US6146404A (en) 1999-09-03 2000-11-14 Scimed Life Systems, Inc. Removable thrombus filter
US6358557B1 (en) 1999-09-10 2002-03-19 Sts Biopolymers, Inc. Graft polymerization of substrate surfaces
US6610013B1 (en) 1999-10-01 2003-08-26 Life Imaging Systems, Inc. 3D ultrasound-guided intraoperative prostate brachytherapy
US6755871B2 (en) 1999-10-15 2004-06-29 R.R. Street & Co. Inc. Cleaning system utilizing an organic cleaning solvent and a pressurized fluid solvent
US7537785B2 (en) 1999-10-29 2009-05-26 Nitromed, Inc. Composition for treating vascular diseases characterized by nitric oxide insufficiency
US6537310B1 (en) 1999-11-19 2003-03-25 Advanced Bio Prosthetic Surfaces, Ltd. Endoluminal implantable devices and method of making same
US6908624B2 (en) 1999-12-23 2005-06-21 Advanced Cardiovascular Systems, Inc. Coating for implantable devices and a method of forming the same
US6572813B1 (en) 2000-01-13 2003-06-03 Advanced Cardiovascular Systems, Inc. Balloon forming process
TWI284048B (en) 2000-01-27 2007-07-21 Zentaris Ag Compressed microparticles for dry injection
EP1132058A1 (fr) 2000-03-06 2001-09-12 Advanced Laser Applications Holding S.A. Prothèse intravasculaire
EP1145719A3 (fr) 2000-03-10 2001-11-14 Pfizer Products Inc. Utilisation d'un sel ferreux pour l'inhibition de la dégradation oxydative de compositions pharmaceutiques
US8088060B2 (en) 2000-03-15 2012-01-03 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
JP2004512059A (ja) 2000-05-12 2004-04-22 アドバンスト・バイオ・プロスゼティック・サーフィスズ・リミテッド 自立型のラミネートされた膜構造材料及び同材料によって製造された医療用装置及びその製造方法
US7217770B2 (en) 2000-05-17 2007-05-15 Samyang Corporation Stable polymeric micelle-type drug composition and method for the preparation thereof
US20020144757A1 (en) 2000-07-07 2002-10-10 Craig Charles Horace Stainless steel alloy with improved radiopaque characteristics
US20030077200A1 (en) 2000-07-07 2003-04-24 Craig Charles H. Enhanced radiopaque alloy stent
CN102871979B (zh) 2000-09-01 2014-10-22 帕尔马亚有限公司 缓释药物制剂及其施用方法
US7332242B2 (en) 2000-09-01 2008-02-19 Itochu Corporation Lithium-based battery having extensible, ion-impermeable polymer covering on the battery container
US6521258B1 (en) 2000-09-08 2003-02-18 Ferro Corporation Polymer matrices prepared by supercritical fluid processing techniques
US6506213B1 (en) 2000-09-08 2003-01-14 Ferro Corporation Manufacturing orthopedic parts using supercritical fluid processing techniques
US6953560B1 (en) 2000-09-28 2005-10-11 Advanced Cardiovascular Systems, Inc. Barriers for polymer-coated implantable medical devices and methods for making the same
US20020111590A1 (en) 2000-09-29 2002-08-15 Davila Luis A. Medical devices, drug coatings and methods for maintaining the drug coatings thereon
US20060222756A1 (en) 2000-09-29 2006-10-05 Cordis Corporation Medical devices, drug coatings and methods of maintaining the drug coatings thereon
US20050084514A1 (en) 2000-11-06 2005-04-21 Afmedica, Inc. Combination drug therapy for reducing scar tissue formation
US20040018228A1 (en) 2000-11-06 2004-01-29 Afmedica, Inc. Compositions and methods for reducing scar tissue formation
AU2002239491A1 (en) 2000-11-09 2002-05-27 Vanderbilt University Methods for the treatment of cancer and other diseases and methods of developing the same
US6682757B1 (en) 2000-11-16 2004-01-27 Euro-Celtique, S.A. Titratable dosage transdermal delivery system
EP1308180B1 (fr) 2000-11-30 2009-08-05 Kabushiki Kaisha Kyoto Iryo Sekkei Endoprothese vasculaire et materiau d'endoprothese vasculaire
US6913617B1 (en) 2000-12-27 2005-07-05 Advanced Cardiovascular Systems, Inc. Method for creating a textured surface on an implantable medical device
GB0100760D0 (en) 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
GB0100761D0 (en) 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
TWI246524B (en) 2001-01-19 2006-01-01 Shearwater Corp Multi-arm block copolymers as drug delivery vehicles
US6660176B2 (en) 2001-01-24 2003-12-09 Virginia Commonwealth University Molecular imprinting of small particles, and production of small particles from solid state reactants
CA2403670C (fr) 2001-01-31 2010-02-09 Rohm Gmbh & Co. Kg Forme galenique multiparticulaire contenant au moins deux formes de granulats enrobes de differentes manieres
US20040220660A1 (en) 2001-02-05 2004-11-04 Shanley John F. Bioresorbable stent with beneficial agent reservoirs
DE10106810A1 (de) 2001-02-14 2002-09-05 Siemens Ag Netzunabhängige Stromversorgungseinheit
US6905555B2 (en) 2001-02-15 2005-06-14 Micell Technologies, Inc. Methods for transferring supercritical fluids in microelectronic and other industrial processes
US6720003B2 (en) 2001-02-16 2004-04-13 Andrx Corporation Serotonin reuptake inhibitor formulations
US6949251B2 (en) 2001-03-02 2005-09-27 Stryker Corporation Porous β-tricalcium phosphate granules for regeneration of bone tissue
AU2002258923A1 (en) 2001-04-24 2002-11-05 Edward J. Kaplan Deflectable implantation device and method for use
US20040022853A1 (en) 2001-04-26 2004-02-05 Control Delivery Systems, Inc. Polymer-based, sustained release drug delivery system
WO2002090085A1 (fr) 2001-05-04 2002-11-14 Trexel Inc Systemes et procedes de moulage par injection
WO2002096389A1 (fr) * 2001-05-30 2002-12-05 Microchips, Inc. Dispositifs reservoirs a micropuce pourvus d'un revetement conforme
US20030044514A1 (en) 2001-06-13 2003-03-06 Richard Robert E. Using supercritical fluids to infuse therapeutic on a medical device
US7485113B2 (en) 2001-06-22 2009-02-03 Johns Hopkins University Method for drug delivery through the vitreous humor
US7501157B2 (en) 2001-06-26 2009-03-10 Accelr8 Technology Corporation Hydroxyl functional surface coating
US7015875B2 (en) 2001-06-29 2006-03-21 Novus Partners Llc Dynamic device for billboard advertising
US6967234B2 (en) 2002-12-18 2005-11-22 Ethicon, Inc. Alkyd-lactone copolymers for medical applications
US6743505B2 (en) 2001-07-27 2004-06-01 Ethicon, Inc. Bioabsorbable multifilament yarn and methods of manufacture
US6669980B2 (en) 2001-09-18 2003-12-30 Scimed Life Systems, Inc. Method for spray-coating medical devices
US6939376B2 (en) 2001-11-05 2005-09-06 Sun Biomedical, Ltd. Drug-delivery endovascular stent and method for treating restenosis
US20030088307A1 (en) 2001-11-05 2003-05-08 Shulze John E. Potent coatings for stents
WO2003039524A1 (fr) 2001-11-09 2003-05-15 Pharmacia Ab Agent anti-muscarinique et agoniste des oestrogenes pour traiter une vessie instable ou hyperactive
US6868123B2 (en) * 2001-12-07 2005-03-15 Motorola, Inc. Programmable motion estimation module with vector array unit
TW497494U (en) 2001-12-28 2002-08-01 Metal Ind Redearch & Amp Dev C Fluid driven stirring device for compressing gas cleaning system
DE10200388A1 (de) 2002-01-08 2003-07-24 Translumina Gmbh Beschichtungssystem
CN1615137A (zh) 2002-01-10 2005-05-11 诺瓦提斯公司 用于预防和治疗血管疾病、包含雷帕霉素及其衍生物的药物递送系统
US20060093771A1 (en) 2002-02-15 2006-05-04 Frantisek Rypacek Polymer coating for medical devices
DE60333955D1 (de) 2002-02-15 2010-10-07 Gilead Palo Alto Inc Polymerbeschichtung für medizinische Geräte
WO2003074992A2 (fr) 2002-03-01 2003-09-12 Mds Proteomics Inc. Proteines phosphorylees et utilisations associees
GB0205868D0 (en) 2002-03-13 2002-04-24 Univ Nottingham Polymer composite with internally distributed deposition matter
US6743463B2 (en) * 2002-03-28 2004-06-01 Scimed Life Systems, Inc. Method for spray-coating a medical device having a tubular wall such as a stent
US7470281B2 (en) 2002-04-26 2008-12-30 Medtronic Vascular, Inc. Coated stent with crimpable coating
US6669785B2 (en) 2002-05-15 2003-12-30 Micell Technologies, Inc. Methods and compositions for etch cleaning microelectronic substrates in carbon dioxide
US6780475B2 (en) 2002-05-28 2004-08-24 Battelle Memorial Institute Electrostatic deposition of particles generated from rapid expansion of supercritical fluid solutions
US6756084B2 (en) * 2002-05-28 2004-06-29 Battelle Memorial Institute Electrostatic deposition of particles generated from rapid expansion of supercritical fluid solutions
US7229837B2 (en) 2002-05-30 2007-06-12 Uchicago Argonne, Llc Enhanced photophysics of conjugated polymers
AU2003237989A1 (en) * 2002-06-13 2003-12-31 Kappler, Inc. Microporous membrane with adsorbent multi-functional filler
US6794902B2 (en) 2002-06-14 2004-09-21 Sun Microsystems, Inc. Virtual ground circuit
CN100471469C (zh) 2002-06-27 2009-03-25 微创医疗器械(上海)有限公司 一种具有多层涂层的药物洗脱支架
US20040013792A1 (en) 2002-07-19 2004-01-22 Samuel Epstein Stent coating holders
JP2004058431A (ja) 2002-07-29 2004-02-26 Nitto Denko Corp 粘着テープ又はシート
US20050019747A1 (en) 2002-08-07 2005-01-27 Anderson Daniel G. Nanoliter-scale synthesis of arrayed biomaterials and screening thereof
US7029495B2 (en) 2002-08-28 2006-04-18 Scimed Life Systems, Inc. Medical devices and methods of making the same
US7060051B2 (en) 2002-09-24 2006-06-13 Scimed Life Systems, Inc. Multi-balloon catheter with hydrogel coating
WO2004028589A2 (fr) 2002-09-26 2004-04-08 Endovascular Devices, Inc. Appareil et procede de distribution de mitomycine au moyen d'un dispositif medical d'elution biocompatible implantable
US7091297B2 (en) 2002-10-11 2006-08-15 The University Of Connecticut Shape memory polymers based on semicrystalline thermoplastic polyurethanes bearing nanostructured hard segments
US6800663B2 (en) 2002-10-18 2004-10-05 Alkermes Controlled Therapeutics Inc. Ii, Crosslinked hydrogel copolymers
KR100511030B1 (ko) 2002-10-21 2005-08-31 한국과학기술연구원 혈액적합성 의료용 금속 재료 및 이의 제조 방법
US7462593B2 (en) 2002-11-07 2008-12-09 Us Gov Health & Human Serv Compositions and methods for promoting angiogenesis
US20060121080A1 (en) 2002-11-13 2006-06-08 Lye Whye K Medical devices having nanoporous layers and methods for making the same
US20040098106A1 (en) 2002-11-14 2004-05-20 Williams Michael S. Intraluminal prostheses and carbon dioxide-assisted methods of impregnating same with pharmacological agents
WO2004045450A2 (fr) 2002-11-15 2004-06-03 Synecor, Llc Endoprotheses ameliorees et procedes de fabrication
JP4371653B2 (ja) 2002-11-25 2009-11-25 テルモ株式会社 体内埋込医療器具
US6790483B2 (en) 2002-12-06 2004-09-14 Eastman Kodak Company Method for producing patterned deposition from compressed fluid
EP1578193A4 (fr) 2002-12-23 2011-06-15 Vical Inc Procede de lyophilisation de complexes d'acide nucleique/copolymere sequence/tensioactif cationique
US7152452B2 (en) 2002-12-26 2006-12-26 Advanced Cardiovascular Systems, Inc. Assembly for crimping an intraluminal device and method of use
US20040143317A1 (en) 2003-01-17 2004-07-22 Stinson Jonathan S. Medical devices
US20050079199A1 (en) 2003-02-18 2005-04-14 Medtronic, Inc. Porous coatings for drug release from medical devices
US20040170685A1 (en) 2003-02-26 2004-09-02 Medivas, Llc Bioactive stents and methods for use thereof
US20080051866A1 (en) 2003-02-26 2008-02-28 Chao Chin Chen Drug delivery devices and methods
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20040193262A1 (en) 2003-03-29 2004-09-30 Shadduck John H. Implants for treating ocular hypertension, methods of use and methods of fabrication
US7527632B2 (en) 2003-03-31 2009-05-05 Cordis Corporation Modified delivery device for coated medical devices
US7326734B2 (en) 2003-04-01 2008-02-05 The Regents Of The University Of California Treatment of bladder and urinary tract cancers
US7537803B2 (en) 2003-04-08 2009-05-26 New Jersey Institute Of Technology Polymer coating/encapsulation of nanoparticles using a supercritical antisolvent process
US20050216075A1 (en) 2003-04-08 2005-09-29 Xingwu Wang Materials and devices of enhanced electromagnetic transparency
US20060102871A1 (en) 2003-04-08 2006-05-18 Xingwu Wang Novel composition
US20050208102A1 (en) 2003-04-09 2005-09-22 Schultz Clyde L Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
US20050038498A1 (en) 2003-04-17 2005-02-17 Nanosys, Inc. Medical device applications of nanostructured surfaces
GB0310300D0 (en) 2003-05-06 2003-06-11 Univ Belfast Nanocomposite drug delivery composition
US7279174B2 (en) 2003-05-08 2007-10-09 Advanced Cardiovascular Systems, Inc. Stent coatings comprising hydrophilic additives
US7553827B2 (en) 2003-08-13 2009-06-30 Depuy Spine, Inc. Transdiscal administration of cycline compounds
US7429378B2 (en) 2003-05-13 2008-09-30 Depuy Spine, Inc. Transdiscal administration of high affinity anti-MMP inhibitors
US20040236416A1 (en) 2003-05-20 2004-11-25 Robert Falotico Increased biocompatibility of implantable medical devices
US7662864B2 (en) 2003-06-04 2010-02-16 Rutgers, The State University Of New Jersey Solution polymerization processes to prepare a polymer that degrades to release a physiologically active agent
WO2004108274A1 (fr) 2003-06-06 2004-12-16 Mitsubishi Chemical Corporation Articles absorbant l'eau et procede de production de ces derniers
WO2004113429A2 (fr) * 2003-06-23 2004-12-29 The University Of Chicago Nanocomposites polyoléfiniques
US7318945B2 (en) 2003-07-09 2008-01-15 Medtronic Vascular, Inc. Laminated drug-polymer coated stent having dipped layers
US8025637B2 (en) 2003-07-18 2011-09-27 Boston Scientific Scimed, Inc. Medical balloons and processes for preparing same
US7169404B2 (en) 2003-07-30 2007-01-30 Advanced Cardiovasular Systems, Inc. Biologically absorbable coatings for implantable devices and methods for fabricating the same
US20050033417A1 (en) 2003-07-31 2005-02-10 John Borges Coating for controlled release of a therapeutic agent
US7318944B2 (en) 2003-08-07 2008-01-15 Medtronic Vascular, Inc. Extrusion process for coating stents
US20050238718A1 (en) * 2003-08-08 2005-10-27 Werner Oberegger Modified-release tablet of bupropion hydrochloride
WO2005027785A2 (fr) 2003-09-18 2005-03-31 Advanced Bio Prosthetic Surfaces, Ltd. Dispositif medical integrant des fonctionnalites de systemes micro-electromecaniques, et procedes de fabrication correspondants
US8801692B2 (en) 2003-09-24 2014-08-12 Medtronic Vascular, Inc. Gradient coated stent and method of fabrication
US20050070990A1 (en) 2003-09-26 2005-03-31 Stinson Jonathan S. Medical devices and methods of making same
US7198675B2 (en) 2003-09-30 2007-04-03 Advanced Cardiovascular Systems Stent mandrel fixture and method for selectively coating surfaces of a stent
US6984411B2 (en) 2003-10-14 2006-01-10 Boston Scientific Scimed, Inc. Method for roll coating multiple stents
EP1675890A1 (fr) 2003-10-23 2006-07-05 The University Of Nottingham Elaboration d'extrudats de polymeres actifs
US20050131513A1 (en) 2003-12-16 2005-06-16 Cook Incorporated Stent catheter with a permanently affixed conductor
CA2549601A1 (fr) 2003-12-24 2005-07-14 Novartis Ag Dispositifs medicaux recouverts de polymeres de carbonate de polyethylene
US20050147734A1 (en) 2004-01-07 2005-07-07 Jan Seppala Method and system for coating tubular medical devices
US20050268573A1 (en) * 2004-01-20 2005-12-08 Avantec Vascular Corporation Package of sensitive articles
US7306677B2 (en) 2004-01-30 2007-12-11 Boston Scientific Corporation Clamping fixture for coating stents, system using the fixture, and method of using the fixture
GB2411078B (en) 2004-02-10 2009-02-04 Samsung Electronics Co Ltd Mobile communications
US7241344B2 (en) 2004-02-10 2007-07-10 Boston Scientific Scimed, Inc. Apparatus and method for electrostatic spray coating of medical devices
EP1732619A1 (fr) 2004-03-26 2006-12-20 SurModics, Inc. Composition et procede permettant de preparer des surfaces biocompatibles
US7335264B2 (en) 2004-04-22 2008-02-26 Boston Scientific Scimed, Inc. Differentially coated medical devices, system for differentially coating medical devices, and coating method
US20050288481A1 (en) 2004-04-30 2005-12-29 Desnoyer Jessica R Design of poly(ester amides) for the control of agent-release from polymeric compositions
US7815922B2 (en) 2004-05-14 2010-10-19 Becton, Dickinson And Company Articles having bioactive surfaces and solvent-free methods of preparation thereof
WO2005117942A2 (fr) 2004-05-14 2005-12-15 The Regents Of The University Of Michigan Procedes d'encapsulation de biomacromolecules dans des polymeres
US7682656B2 (en) 2004-06-14 2010-03-23 Agruim Inc. Process and apparatus for producing a coated product
CA2511212A1 (fr) 2004-07-02 2006-01-02 Henkel Kommanditgesellschaft Auf Aktien Conditionneur de surface pour systemes de revetement en poudre
EP2359842A1 (fr) 2004-07-14 2011-08-24 University of Utah Research Foundation Compositions et utilisations liees a des netrines
US20060020325A1 (en) 2004-07-26 2006-01-26 Robert Burgermeister Material for high strength, controlled recoil stent
US8541078B2 (en) * 2004-08-06 2013-09-24 Societe Bic Fuel supplies for fuel cells
US8119153B2 (en) 2004-08-26 2012-02-21 Boston Scientific Scimed, Inc. Stents with drug eluting coatings
US20080077232A1 (en) 2004-09-08 2008-03-27 Kaneka Corporation Stent for Placement in Body
JP2008514706A (ja) 2004-09-29 2008-05-08 コーディス・コーポレイション 安定非晶質ラパマイシン様化合物の薬学的投与形態
US8313763B2 (en) 2004-10-04 2012-11-20 Tolmar Therapeutics, Inc. Sustained delivery formulations of rapamycin compounds
US20060093643A1 (en) 2004-11-04 2006-05-04 Stenzel Eric B Medical device for delivering therapeutic agents over different time periods
US7455688B2 (en) 2004-11-12 2008-11-25 Con Interventional Systems, Inc. Ostial stent
WO2006063021A2 (fr) 2004-12-07 2006-06-15 Surmodics, Inc. Revetements comprenant un ou plusieurs agents actifs cristallises et methodes associees
US20070059350A1 (en) 2004-12-13 2007-03-15 Kennedy John P Agents for controlling biological fluids and methods of use thereof
CA2527666C (fr) 2004-12-16 2008-09-23 Miv Therapeutics Inc. Dispositif d'administration de medicament multicouche et methode de fabrication connexe
US7632307B2 (en) 2004-12-16 2009-12-15 Advanced Cardiovascular Systems, Inc. Abluminal, multilayer coating constructs for drug-delivery stents
US8292944B2 (en) 2004-12-17 2012-10-23 Reva Medical, Inc. Slide-and-lock stent
US20060198868A1 (en) 2005-01-05 2006-09-07 Dewitt David M Biodegradable coating compositions comprising blends
US7727273B2 (en) 2005-01-13 2010-06-01 Boston Scientific Scimed, Inc. Medical devices and methods of making the same
US7772352B2 (en) 2005-01-28 2010-08-10 Bezwada Biomedical Llc Bioabsorbable and biocompatible polyurethanes and polyamides for medical devices
WO2006110197A2 (fr) 2005-03-03 2006-10-19 Icon Medical Corp. Dispositif medical en polymere biodegradable
US7837726B2 (en) 2005-03-14 2010-11-23 Abbott Laboratories Visible endoprosthesis
WO2006099276A2 (fr) 2005-03-14 2006-09-21 3M Innovative Properties Company Composes de polymeres biocompatibles pour preparations medicales
WO2006101972A2 (fr) 2005-03-17 2006-09-28 Elan Pharma International Limited Compositions injectables de composes nanoparticulaires immunosuppresseurs
EP2327429B1 (fr) 2005-03-23 2014-09-17 Abbott Laboratories Administration d'agents lipophiles par dispositifs médicaux
US20070009564A1 (en) 2005-06-22 2007-01-11 Mcclain James B Drug/polymer composite materials and methods of making the same
AU2006270221B2 (en) * 2005-07-15 2012-01-19 Micell Technologies, Inc. Polymer coatings containing drug powder of controlled morphology
WO2007011708A2 (fr) 2005-07-15 2007-01-25 Micell Technologies, Inc. Stent a revetement polymere renfermant de la rapamycine amorphe
EP1912614A4 (fr) * 2005-08-03 2009-08-05 Univ Western Ontario Enrobage direct de formes posologiques solides effectue au moyen de materiaux pulverulents
WO2007022055A1 (fr) 2005-08-12 2007-02-22 Massicotte J Mathieu Procede et dispositif d'extraction d'objets du corps
EP1764116A1 (fr) 2005-09-16 2007-03-21 Debiotech S.A. Production d'un revêtement poreux à l'aide des particules colloidales
US7935379B2 (en) 2005-11-14 2011-05-03 Boston Scientific Scimed, Inc. Coated and imprinted medical devices and methods of making the same
US20070196423A1 (en) 2005-11-21 2007-08-23 Med Institute, Inc. Implantable medical device coatings with biodegradable elastomer and releasable therapeutic agent
DK1957130T3 (da) 2005-12-09 2010-11-22 Dsm Ip Assets Bv Hydrofilt overtræk omfattende en polyelektrolyt
US20070148251A1 (en) 2005-12-22 2007-06-28 Hossainy Syed F A Nanoparticle releasing medical devices
US7919108B2 (en) 2006-03-10 2011-04-05 Cook Incorporated Taxane coatings for implantable medical devices
JP2009525768A (ja) 2006-01-27 2009-07-16 エム イー ディ インスチィチュート インク 薬物の制御放出用ナノコンポジットコーティングを伴う器具
US20070203569A1 (en) 2006-02-24 2007-08-30 Robert Burgermeister Implantable device formed from polymer blends having modified molecular structures
US7955383B2 (en) 2006-04-25 2011-06-07 Medtronics Vascular, Inc. Laminated implantable medical device having a metallic coating
WO2007127363A2 (fr) 2006-04-26 2007-11-08 Micell Technologies, Inc. Revêtements contenant plusieurs médicaments
US7691400B2 (en) 2006-05-05 2010-04-06 Medtronic Vascular, Inc. Medical device having coating with zeolite drug reservoirs
US20070281117A1 (en) 2006-06-02 2007-12-06 Xtent, Inc. Use of plasma in formation of biodegradable stent coating
BRPI0603437A2 (pt) 2006-06-06 2010-07-06 Luiz Gonzaga Granja Jr prótese para anastomose tipo stent extraluminal
US20080124372A1 (en) 2006-06-06 2008-05-29 Hossainy Syed F A Morphology profiles for control of agent release rates from polymer matrices
JP6049160B2 (ja) 2006-09-13 2016-12-27 エリクシアー メディカル コーポレイション 大環状ラクトン化合物およびその使用方法
US20080075753A1 (en) 2006-09-25 2008-03-27 Chappa Ralph A Multi-layered coatings and methods for controlling elution of active agents
US8636767B2 (en) 2006-10-02 2014-01-28 Micell Technologies, Inc. Surgical sutures having increased strength
EP1913960A1 (fr) 2006-10-19 2008-04-23 Albert Schömig implant enrobé
EP1916006A1 (fr) 2006-10-19 2008-04-30 Albert Schömig Implant revêtu de cire ou de résine
US20080097591A1 (en) * 2006-10-20 2008-04-24 Biosensors International Group Drug-delivery endovascular stent and method of use
US7959942B2 (en) 2006-10-20 2011-06-14 Orbusneich Medical, Inc. Bioabsorbable medical device with coating
EP2081694B1 (fr) 2006-10-23 2020-05-13 Micell Technologies, Inc. Support pour charger électriquement un substrat au cours de l'enduction
US8430055B2 (en) 2008-08-29 2013-04-30 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
CA2672496A1 (fr) 2006-12-13 2008-06-19 Angiotech Pharmaceuticals, Inc. Implants medicaux avec une combinaison de paclitaxel et de dipyridamole
US8114466B2 (en) 2007-01-03 2012-02-14 Boston Scientific Scimed, Inc. Methods of applying coating to the inside surface of a stent
JP5603598B2 (ja) 2007-01-08 2014-10-08 ミセル テクノロジーズ、インコーポレイテッド 生物分解層を有するステント
US20130150943A1 (en) 2007-01-19 2013-06-13 Elixir Medical Corporation Biodegradable endoprostheses and methods for their fabrication
US7745566B2 (en) 2007-01-23 2010-06-29 Ferro Corporation Methods for the purification of polymers
US7887830B2 (en) 2007-02-27 2011-02-15 Boston Scientific Scimed, Inc. Medical devices having polymeric regions based on styrene-isobutylene copolymers
WO2008124634A1 (fr) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Micelles inverses encapsulées par un polymère
US20100211164A1 (en) 2007-04-17 2010-08-19 Mcclain James B Stents having biodegradable layers
WO2008137148A2 (fr) 2007-05-03 2008-11-13 Abraxis Bioscience, Llc Procédés et compositions permettant le traitement de l'hypertension pulmonaire
GB0709517D0 (en) 2007-05-17 2007-06-27 Queen Mary & Westfield College An electrostatic spraying device and a method of electrostatic spraying
US7952706B2 (en) 2007-05-17 2011-05-31 Prescient Medical, Inc. Multi-channel fiber optic spectroscopy systems employing integrated optics modules
EP2170418B1 (fr) 2007-05-25 2016-03-16 Micell Technologies, Inc. Films de polymères pour le revêtement des dispositifs médicaux
US7922760B2 (en) 2007-05-29 2011-04-12 Abbott Cardiovascular Systems Inc. In situ trapping and delivery of agent by a stent having trans-strut depots
US20090068266A1 (en) 2007-09-11 2009-03-12 Raheja Praveen Sirolimus having specific particle size and pharmaceutical compositions thereof
US20090076446A1 (en) 2007-09-14 2009-03-19 Quest Medical, Inc. Adjustable catheter for dilation in the ear, nose or throat
JP5114788B2 (ja) 2007-09-28 2013-01-09 三菱重工業株式会社 リチウム二次電池
PL2214646T3 (pl) 2007-10-05 2021-12-20 Wayne State University Dendrymery do przedłużonego uwalniania związków
WO2009051780A1 (fr) 2007-10-19 2009-04-23 Micell Technologies, Inc. Endoprothèses vasculaires revêtues de médicament
EP3025685B1 (fr) 2007-10-19 2019-07-17 CeloNova Biosciences, Inc. Stents implantables et de soutien de la lumiere
US20090111787A1 (en) 2007-10-31 2009-04-30 Florencia Lim Polymer blends for drug delivery stent matrix with improved thermal stability
US8642062B2 (en) 2007-10-31 2014-02-04 Abbott Cardiovascular Systems Inc. Implantable device having a slow dissolving polymer
US20090202609A1 (en) 2008-01-06 2009-08-13 Keough Steven J Medical device with coating composition
US20100042206A1 (en) 2008-03-04 2010-02-18 Icon Medical Corp. Bioabsorbable coatings for medical devices
US20090227948A1 (en) 2008-03-06 2009-09-10 Boston Scientific Scimed, Inc. Balloon catheter devices with sheath covering
SG192523A1 (en) 2008-04-17 2013-08-30 Micell Technologies Inc Stents having bioabsorbable layers
US8557273B2 (en) 2008-04-18 2013-10-15 Medtronic, Inc. Medical devices and methods including polymers having biologically active agents therein
US20110143429A1 (en) 2008-04-30 2011-06-16 Iksoo Chun Tissue engineered blood vessels
US8703302B2 (en) 2008-05-08 2014-04-22 Nippon Steel & Sumikin Chemical Co., Ltd. Indolocarbazole derivative with aromatic phosphne oxide group for organic electroluminescent device and organic electroluminescent device containing same
US8298607B2 (en) 2008-05-15 2012-10-30 Abbott Cardiovascular Systems Inc. Method for electrostatic coating of a medical device
US20090297578A1 (en) 2008-06-03 2009-12-03 Trollsas Mikael O Biosoluble coating comprising anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders
CN102159257B (zh) 2008-07-17 2015-11-25 米歇尔技术公司 药物递送医疗设备
US20100055145A1 (en) 2008-08-29 2010-03-04 Biosensors International Group Stent coatings for reducing late stent thrombosis
US8367090B2 (en) 2008-09-05 2013-02-05 Abbott Cardiovascular Systems Inc. Coating on a balloon comprising a polymer and a drug
US20120064143A1 (en) 2008-11-11 2012-03-15 The Board Of Regents Of The University Of Texas System Inhibition of mammalian target of rapamycin
US8834913B2 (en) 2008-12-26 2014-09-16 Battelle Memorial Institute Medical implants and methods of making medical implants
CA2748273C (fr) 2008-12-26 2018-01-09 Battelle Memorial Institute Implants medicaux et procedes de fabrication associes
US20100198330A1 (en) 2009-02-02 2010-08-05 Hossainy Syed F A Bioabsorbable Stent And Treatment That Elicits Time-Varying Host-Material Response
US9572692B2 (en) 2009-02-02 2017-02-21 Abbott Cardiovascular Systems Inc. Bioabsorbable stent that modulates plaque geometric morphology and chemical composition
US20100241220A1 (en) 2009-03-23 2010-09-23 Mcclain James B Peripheral Stents Having Layers
US20100239635A1 (en) 2009-03-23 2010-09-23 Micell Technologies, Inc. Drug delivery medical device
EP2411440B1 (fr) 2009-03-23 2018-01-17 Micell Technologies, Inc. Polymères biodégradables améliorés
CA2757276C (fr) 2009-04-01 2017-06-06 Micell Technologies, Inc. Endoprotheses enduites
US20110301697A1 (en) 2009-04-10 2011-12-08 Hemoteq Ag Manufacture, method and use of drug-eluting medical devices for permanently keeping blood vessels open
CA2759015C (fr) 2009-04-17 2017-06-20 James B. Mcclain Endoprotheses vasculaires ayant une elution controlee
EP2266507B1 (fr) 2009-06-22 2015-07-29 Biotronik VI Patent AG Stent ayant un design amélioré
US9327060B2 (en) 2009-07-09 2016-05-03 CARDINAL HEALTH SWITZERLAND 515 GmbH Rapamycin reservoir eluting stent
EP2453834A4 (fr) 2009-07-16 2014-04-16 Micell Technologies Inc Dispositif médical distributeur de médicament
US8039147B2 (en) 2009-08-27 2011-10-18 Sb Limotive Co., Ltd. Rechargeable secondary battery having improved safety against puncture and collapse
EP2531140B1 (fr) 2010-02-02 2017-11-01 Micell Technologies, Inc. Endoprothèse et système de pose d'endoprothèse avec une capacité améliorée de pose
US8795762B2 (en) 2010-03-26 2014-08-05 Battelle Memorial Institute System and method for enhanced electrostatic deposition and surface coatings
WO2011130448A1 (fr) 2010-04-16 2011-10-20 Micell Technologies, Inc. Endoprothèses vasculaires ayant une élution contrôlée
CA2797110C (fr) 2010-04-22 2020-07-21 Micell Technologies, Inc. Endoprotheses et autres dispositifs ayant un revetement de matrice extracellulaire
WO2012009684A2 (fr) 2010-07-16 2012-01-19 Micell Technologies, Inc. Dispositif médical d'administration de médicament
CA2810842C (fr) 2010-09-09 2018-06-26 Micell Technologies, Inc. Formes pharmaceutiques de type macrolides
US20120150275A1 (en) 2010-12-10 2012-06-14 Micropen Technologies Corporation Stents and methods of making stents
CA2823355C (fr) 2010-12-30 2017-08-22 Micell Technologies, Inc. Nanoparticules et revetements particulaires modifies en surface, ballonnets revetus et procedes associes
US20120323311A1 (en) 2011-04-13 2012-12-20 Micell Technologies, Inc. Stents having controlled elution
US20120280432A1 (en) 2011-05-06 2012-11-08 Industrial Technology Research Institute Method for manufacturing bioabsorbable stents
US10464100B2 (en) 2011-05-31 2019-11-05 Micell Technologies, Inc. System and process for formation of a time-released, drug-eluting transferable coating
CA2841360A1 (fr) 2011-07-15 2013-01-24 Micell Technologies, Inc. Dispositif medical d'administration de medicament
WO2013025535A1 (fr) 2011-08-12 2013-02-21 Micell Technologies, Inc. Endoprothèses ayant une élution régulée
WO2013059509A1 (fr) 2011-10-18 2013-04-25 Micell Technologies, Inc. Dispositif médical d'administration de médicament
WO2013177211A1 (fr) 2012-05-21 2013-11-28 Micell Technologies, Inc. Endoprothèse à élution de médicament sûre dotée d'un enrobage absorbable
WO2013173657A1 (fr) 2012-05-16 2013-11-21 Micell Technologies, Inc. Compositions d'agent lipophile et biologique à libération prolongée à faible taux de bouffée
JP2015533305A (ja) 2012-10-18 2015-11-24 ミセル テクノロジーズ，インク． 薬物送達医療デバイス

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6524698B1 (en) * 1990-09-27 2003-02-25 Helmuth Schmoock Fluid impermeable foil
US20050003074A1 (en) * 1996-11-13 2005-01-06 Phoqus Pharmaceuticals Limited Method and apparatus for the coating of substrates for pharmaceutical use
US6627246B2 (en) * 2000-05-16 2003-09-30 Ortho-Mcneil Pharmaceutical, Inc. Process for coating stents and other medical devices using super-critical carbon dioxide
US20030143315A1 (en) * 2001-05-16 2003-07-31 Pui David Y H Coating medical devices
US7201940B1 (en) * 2001-06-12 2007-04-10 Advanced Cardiovascular Systems, Inc. Method and apparatus for thermal spray processing of medical devices
US20060121089A1 (en) * 2002-03-20 2006-06-08 Advanced Cardiovascular Systems, Inc. Coatings for implantable medical devices
US20030222018A1 (en) 2002-05-28 2003-12-04 Battelle Memorial Institute Methods for producing films using supercritical fluid
WO2003101624A1 (fr) 2002-05-28 2003-12-11 Battelle Memorial Institute Depot electrostatique de particules issues de l'expansion rapide de solutions fluides supercritiques
US20030031699A1 (en) * 2002-09-30 2003-02-13 Medtronic Minimed, Inc. Polymer compositions containing bioactive agents and methods for their use
US20050196424A1 (en) * 2003-05-02 2005-09-08 Chappa Ralph A. Medical devices and methods for producing the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2170418A4

Cited By (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8703066B2 (en) 2004-01-07 2014-04-22 Noxilizer, Inc. Sterilization system and method
US9180217B2 (en) 2004-01-07 2015-11-10 Noxilizer, Inc. Sterilization system and device
US8017074B2 (en) 2004-01-07 2011-09-13 Noxilizer, Inc. Sterilization system and device
US8808622B2 (en) 2004-01-07 2014-08-19 Noxilizer, Inc. Sterilization system and device
US8758429B2 (en) 2005-07-15 2014-06-24 Micell Technologies, Inc. Polymer coatings containing drug powder of controlled morphology
US9827117B2 (en) 2005-07-15 2017-11-28 Micell Technologies, Inc. Polymer coatings containing drug powder of controlled morphology
US10898353B2 (en) 2005-07-15 2021-01-26 Micell Technologies, Inc. Polymer coatings containing drug powder of controlled morphology
US10835396B2 (en) 2005-07-15 2020-11-17 Micell Technologies, Inc. Stent with polymer coating containing amorphous rapamycin
US11911301B2 (en) 2005-07-15 2024-02-27 Micell Medtech Inc. Polymer coatings containing drug powder of controlled morphology
US9737645B2 (en) 2006-04-26 2017-08-22 Micell Technologies, Inc. Coatings containing multiple drugs
US11007307B2 (en) 2006-04-26 2021-05-18 Micell Technologies, Inc. Coatings containing multiple drugs
US11850333B2 (en) 2006-04-26 2023-12-26 Micell Medtech Inc. Coatings containing multiple drugs
US8852625B2 (en) 2006-04-26 2014-10-07 Micell Technologies, Inc. Coatings containing multiple drugs
US9415142B2 (en) 2006-04-26 2016-08-16 Micell Technologies, Inc. Coatings containing multiple drugs
US9539593B2 (en) 2006-10-23 2017-01-10 Micell Technologies, Inc. Holder for electrically charging a substrate during coating
US11426494B2 (en) 2007-01-08 2022-08-30 MT Acquisition Holdings LLC Stents having biodegradable layers
US9737642B2 (en) 2007-01-08 2017-08-22 Micell Technologies, Inc. Stents having biodegradable layers
US10617795B2 (en) 2007-01-08 2020-04-14 Micell Technologies, Inc. Stents having biodegradable layers
US9486338B2 (en) 2007-04-17 2016-11-08 Micell Technologies, Inc. Stents having controlled elution
US9775729B2 (en) 2007-04-17 2017-10-03 Micell Technologies, Inc. Stents having controlled elution
US9433516B2 (en) 2007-04-17 2016-09-06 Micell Technologies, Inc. Stents having controlled elution
US8900651B2 (en) 2007-05-25 2014-12-02 Micell Technologies, Inc. Polymer films for medical device coating
US10350333B2 (en) 2008-04-17 2019-07-16 Micell Technologies, Inc. Stents having bioabsorable layers
US9789233B2 (en) 2008-04-17 2017-10-17 Micell Technologies, Inc. Stents having bioabsorbable layers
US10350391B2 (en) 2008-07-17 2019-07-16 Micell Technologies, Inc. Drug delivery medical device
WO2010009335A1 (fr) 2008-07-17 2010-01-21 Micell Technologies, Inc. Dispositif médical d’administration de médicament
US9510856B2 (en) 2008-07-17 2016-12-06 Micell Technologies, Inc. Drug delivery medical device
US9486431B2 (en) 2008-07-17 2016-11-08 Micell Technologies, Inc. Drug delivery medical device
US8834913B2 (en) 2008-12-26 2014-09-16 Battelle Memorial Institute Medical implants and methods of making medical implants
US8721984B2 (en) 2009-02-23 2014-05-13 Noxilizer, Inc. Device and method for gas sterilization
US8425837B2 (en) 2009-02-23 2013-04-23 Noxilizer, Inc. Device and method for gas sterilization
WO2010111232A2 (fr) 2009-03-23 2010-09-30 Micell Technologies, Inc. Dispositif médical d'administration de médicament
US9981072B2 (en) 2009-04-01 2018-05-29 Micell Technologies, Inc. Coated stents
CN102481195B (zh) * 2009-04-01 2015-03-25 米歇尔技术公司 涂覆支架
CN102481195A (zh) * 2009-04-01 2012-05-30 米歇尔技术公司 涂覆支架
US10653820B2 (en) 2009-04-01 2020-05-19 Micell Technologies, Inc. Coated stents
US11369498B2 (en) 2010-02-02 2022-06-28 MT Acquisition Holdings LLC Stent and stent delivery system with improved deliverability
US8795762B2 (en) 2010-03-26 2014-08-05 Battelle Memorial Institute System and method for enhanced electrostatic deposition and surface coatings
US9687864B2 (en) 2010-03-26 2017-06-27 Battelle Memorial Institute System and method for enhanced electrostatic deposition and surface coatings
US10232092B2 (en) 2010-04-22 2019-03-19 Micell Technologies, Inc. Stents and other devices having extracellular matrix coating
WO2011136882A1 (fr) * 2010-04-29 2011-11-03 Medtronic Vascular Inc. Système et procédé de fabrication d'une endoprothèse
US8377365B2 (en) 2010-04-29 2013-02-19 Medtronic Vascular, Inc. System and method for stent manufacture
WO2012009684A2 (fr) 2010-07-16 2012-01-19 Micell Technologies, Inc. Dispositif médical d'administration de médicament
US11904118B2 (en) 2010-07-16 2024-02-20 Micell Medtech Inc. Drug delivery medical device
US9636309B2 (en) 2010-09-09 2017-05-02 Micell Technologies, Inc. Macrolide dosage forms
US10293050B2 (en) 2010-09-09 2019-05-21 Micell Technologies, Inc. Macrolide dosage forms
WO2012092504A2 (fr) 2010-12-30 2012-07-05 Micell Technologies, Inc. Nanoparticules et revêtements particulaires modifiés en surface, ballonnets revêtus et procédés associés
US10464100B2 (en) 2011-05-31 2019-11-05 Micell Technologies, Inc. System and process for formation of a time-released, drug-eluting transferable coating
US10729819B2 (en) 2011-07-15 2020-08-04 Micell Technologies, Inc. Drug delivery medical device
US10117972B2 (en) 2011-07-15 2018-11-06 Micell Technologies, Inc. Drug delivery medical device
US10188772B2 (en) 2011-10-18 2019-01-29 Micell Technologies, Inc. Drug delivery medical device
WO2013059509A1 (fr) 2011-10-18 2013-04-25 Micell Technologies, Inc. Dispositif médical d'administration de médicament
US11039943B2 (en) 2013-03-12 2021-06-22 Micell Technologies, Inc. Bioabsorbable biomedical implants
US10272606B2 (en) 2013-05-15 2019-04-30 Micell Technologies, Inc. Bioabsorbable biomedical implants
US20210282947A1 (en) * 2017-12-14 2021-09-16 Boston Scientific Scimed, Inc. Stent including an expandable member

Also Published As

Publication number Publication date
EP2170418A4 (fr) 2011-11-09
AU2012203203B2 (en) 2014-10-30
JP2010527746A (ja) 2010-08-19
AU2012203203A1 (en) 2012-06-21
US8900651B2 (en) 2014-12-02
US20100228348A1 (en) 2010-09-09
EP2170418A1 (fr) 2010-04-07
AU2008256684B2 (en) 2012-06-14
CN101815540A (zh) 2010-08-25
AU2008256684A1 (en) 2008-12-04
CA2688314C (fr) 2013-12-03
CA2688314A1 (fr) 2008-12-04
IL202321A (en) 2014-08-31
CN101815540B (zh) 2015-08-19
EP2170418B1 (fr) 2016-03-16
IL202321A0 (en) 2010-06-30

Similar Documents

Publication Publication Date Title
US8900651B2 (en) Polymer films for medical device coating
JP2010527746A5 (fr)
US11911301B2 (en) Polymer coatings containing drug powder of controlled morphology
US11007307B2 (en) Coatings containing multiple drugs
CA2495181A1 (fr) Systeme d'administration d'agent actif comprenant un polymere hydrophile, dispositif medical et procede associe
WO2006002112A1 (fr) Dispositifs, articles, revetements et procedes de liberation controlee d'un agent actif
WO2012058274A2 (fr) Revêtements et procédés pour élution contrôlée d'agents actifs hydrophiles
JP5507570B2 (ja) 植え込み可能な医療装置
KR101492545B1 (ko) 제어된 형태의 약물 분말을 함유하는 중합체 코팅

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880100102.3

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08756215

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2010510441

Country of ref document: JP

Ref document number: 2688314

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 7740/DELNP/2009

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2008256684

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2008756215

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2008256684

Country of ref document: AU

Date of ref document: 20080523

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12601101

Country of ref document: US